tag:blogger.com,1999:blog-14180320585378492552024-03-19T02:00:10.242-07:00Rashmi's blog on microbiologyrashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.comBlogger65125tag:blogger.com,1999:blog-1418032058537849255.post-38696735820048265722016-02-10T20:37:00.000-08:002016-02-10T20:37:10.589-08:00New safer polio strains for use in production of vaccines<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Poliovirus causes a debilitating and sometimes fatal paralytic disease, poliomyelitis, especially in infants and young children. There is no treatment, but safe and effective vaccines have been available since the 1950s. At one time polio was prevalent in many parts of the world but with the widespread use of polio vaccines, polio is very close to being completely eradicated from most of the countries. Soon the world will be polio free, and it will be critical to safeguard this eradication. Scientists are concerned that current vaccines could lead to the reemergence of polio virus in a polio-free world, and there is a need to develop safer strains of polio that can be used in future vaccines.</div>
<div class="MsoNormal">
In a recently published study in <a href="http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1005316">PLoS Pathogens</a>, Sarah Knowlson and colleague show that they have designed
extremely genetically stable, and hyper-attenuated polio strains, which cannot
revert to a dangerous wild-type form. The authors believe that these strains
will be ideal candidates to develop vaccines for polio. The study shows that these new strains not only produce
acceptable virus titers in culture but also have the same antigenic and
immunogenic properties as the parent strains.</div>
<div class="MsoNormal">
<o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
There are
two major types of polio vaccine that are currently used: inactivated polio vaccine (IPV) and oral
polio vaccine (OPV). Inactivated vaccines (also called Salk IPV) use inactive
or killed polioviruses and are given by injection. Oral polio vaccines (also
called Sabin vaccines) are live vaccines that are attenuated /weakened my
multiple passages in culture are as the name denotes are given orally. Both
vaccines are used currently with OPV being more used in areas where polio is
endemic. However, both vaccines are not suitable for long-term use; Sabin or
OPV strains can revert to wild type strains, and production of IPV requires
growth of large amounts of wild-type viruses thus posing a security risk. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Sarah Knowlson and colleagues at the Department of Virology
of National Institute for Biological Standards and Control used the attenuated
Sabin type3 vaccine as a starting strain and generated four new successively
weaker strains by introducing some changes in viral RNA. To examine if these
strains are fit for vaccine production the authors compared them to the
original Sabin strain and the IPV strain. They compared growth properties,
genetic stability and neuro-virulence of these new strains through different
experiments.<span style="mso-spacerun: yes;"> </span>Their results show that
these new viruses produce acceptable viral titers in culture and are
genetically stable. They also noted that these strains were safe to use, as
they did not cause paralysis in the mice. WHO has recently recommended that
once the global eradication of polio is confirmed, the use of all polio vaccine
will be ceased to minimize reintroduction of polio in a polio-free world. The
authors believe that the new strains that they have developed could be used as
a potential vaccine in future after further testing to confirm their genetic
stability and low neuro-virulence.<o:p></o:p></div>
<!--[if gte mso 9]><xml>
<o:DocumentProperties>
<o:Revision>0</o:Revision>
<o:TotalTime>0</o:TotalTime>
<o:Pages>1</o:Pages>
<o:Words>469</o:Words>
<o:Characters>2678</o:Characters>
<o:Company>UCSF</o:Company>
<o:Lines>22</o:Lines>
<o:Paragraphs>6</o:Paragraphs>
<o:CharactersWithSpaces>3141</o:CharactersWithSpaces>
<o:Version>14.0</o:Version>
</o:DocumentProperties>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>JA</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
<w:UseFELayout/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="276">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;}
</style>
<![endif]-->
<!--StartFragment-->
<!--EndFragment--><br />
<div class="MsoNormal">
<br /></div>
</div>
rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-51084821249953876502015-12-08T14:19:00.001-08:002015-12-08T14:19:20.139-08:00Antihistamines for treatment of Hepatitis C virus<div dir="ltr" style="text-align: left;" trbidi="on">
Common over the counter antihistamine chlorcyclizine can treat Hepatitis C virus infection, a new study reports. Hepatitis C causes chronic viral infection, and many individuals are unaware of their infection status as often there are no symptoms. However, if left untreated Hepatitis C infection can lead to the development of liver diseases. Studies speculate that up to 50% of hepatocellular carcinoma incidents, one of the main causes of cancer-related death is the US, are due to chronic and untreated Hepatitis C infection.<br />
At present there is no effective vaccine for Hepatitis C virus. Therapeutic treatments are available and involve a combination of drugs. The treatment of Hepatitis C is very costly with some direct acting drugs costing up to 80,000 USD per patient. Also, some of the drugs are targeted towards specific genotypes of the virus and do no treat all types of Hepatitis C infection. Thus, there is an immense requirement to find and develop new effective and affordable therapy for Hepatitis C infection.<br />
In this study published in prestigious <a href="http://stm.sciencemag.org/content/7/282/282ra49">Science Translational Medicine</a> journal, the authors screened many FDA-approved drugs for their activity against Hepatitis C. They observed some H1-antihistamines that were effective. Of these chlorcyclizine HCl (CCZ), showed high antiviral activity.<br />
Histamines are chemical compounds released during allergic reactions, and H-1 antihistamines are the compounds that oppose the activity of a particular histamine receptor – H1 receptor, in this case, thus helping in reducing allergy symptoms. These are available as over the counter medications. The authors suggested that CCZ exerts its effect by inhibiting early stages of viral infection however they could not confirm which exact stage and further studies are need to understand that. As Hepatitis C treatment, in general, involves many anti-Hepatitis C drugs, the authors wanted to know if CCZ could be used together with those drugs. So, they performed assays to evaluate the effectiveness of CCZ in combination with common anti-Hepatitis C drugs, they observed that combination led to higher anti-Hepatitis C effect than using single drugs. To assess the specificity of CCZ against Hepatitis C, the authors tested 13 other viruses including Herpes Simplex 1, influenza A and hepatitis A virus and noted that CCZ showed no antiviral activity against them. Last but not the least the authors tested if the use of CCZ would lead to the development of viral resistance. For this, they used a chimeric mouse model and exposed it to Hepatitis C virus. They did not observe any rebound during the treatment period of 4-6 weeks, and viral titers continued to decrease. These results suggest the lack of emergence of any drug-resistant strain.<br />
<br />
The results of this study are encouraging, and the authors hope that h1 antihistamines might provide an affordable treatment option for Hepatitis C. Thorough clinical studies of CCZ are needed to determine their effectiveness in treating the virus.<br />
<br />
<div>
<br /></div>
</div>
rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-90334242142545859562015-08-15T22:58:00.001-07:002015-08-15T22:58:56.457-07:00Imperfect vaccines may increase transmission of highly virulent pathogens<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal">
Vaccines that let the host
live but do not prevent transmission of the pathogen are called leaky or
imperfect vaccines. In the early 2000s, it was proposed that such vaccines
could lead to the emergence of highly virulent pathogens by creating ecological
conditions that would allow the emergence of hotter and deadlier strains. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
A recent article published in
July issue of PLos <a href="http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002198">Biology</a>,
investigated this theory. In this study, the authors used Marek’s disease (MD)
virus to show experimentally that immunization of chickens with a vaccine
against MD virus can create conditions that promote transmission of lethal
strains of the virus.<span style="mso-spacerun: yes;"> </span>MD virus is a
highly contagious oncogenic virus of poultry. At present, all MD virus vaccines
are live viruses. The vaccinated birds can become infected and shed wild type
viruses. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
The authors performed a
series of experiments to show that vaccination with MD vaccine increases the
infectious period of the most virulent strain of MD virus by preventing the
death of the host. As virulent strains have a deadly effect on the host, they
are eliminated before infecting other hosts. The prolonged infectious period
causes more shedding of the virus in the environment. They also showed that all
the unvaccinated birds co-housed with vaccinated infected birds became infected
and died.<span style="mso-spacerun: yes;"> </span>Thus, vaccination allowed
onward transmission of most virulent strains and could be risky for
unvaccinated birds.<span style="mso-spacerun: yes;"> </span><o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<!--[if gte mso 9]><xml>
<o:DocumentProperties>
<o:Revision>0</o:Revision>
<o:TotalTime>0</o:TotalTime>
<o:Pages>1</o:Pages>
<o:Words>301</o:Words>
<o:Characters>1719</o:Characters>
<o:Company>UCSF</o:Company>
<o:Lines>14</o:Lines>
<o:Paragraphs>4</o:Paragraphs>
<o:CharactersWithSpaces>2016</o:CharactersWithSpaces>
<o:Version>14.0</o:Version>
</o:DocumentProperties>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>JA</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
<w:UseFELayout/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="276">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;}
</style>
<![endif]-->
<!--StartFragment-->
<!--EndFragment--></div>
<div class="MsoNormal">
The authors note that their
data doesn’t show that vaccination caused the evolution of more virulent
strains of MD virus. They further emphasize that despite the evolution of
deadly strains, vaccination has greatly reduced the mortality due to MD
viruses. Previous studies have observed that more virulent pathogens are
overcoming more effective vaccines. A vaccine that not only protects host but
also prevents onward transmission of the virus could be an answer to this
problem.<span style="font-size: 14pt;"><o:p></o:p></span></div>
</div>
rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-80541158810931203342015-03-05T14:59:00.000-08:002015-03-05T14:59:02.959-08:00A new biomarker for assessing resistance to therapy in rheumatoid arthritis<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
According to a recently published study, low expression of
CD39 on regulatory T cells (Tregs) could be used as a biomarker for resistance
to methotrexate (MTX) therapy in rheumatoid arthritis (RA). MTX, an
antimetabolic drug, is the first line of therapy for RA patients. However, up
to 40% of patients are unresponsive to MTX (or UR-MTX resistant). There is a
need to early diagnose MTX resistance as the resistance generally appears after
3 months of therapy and that means worsening of RA symptoms during that time.
The study published in <a href="http://www.pnas.org/content/112/8/2509.long">January
issue of PNAS</a> shows that low expression of CD39 on circulating Tregs is a
rapid, reliable and convenient biomarker for MTX resistance. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
RA is an inflammatory autoimmune disease associated with
joint destruction and severe morbidity. MTX has been generally used as drug to
treat RA. MTX has two known functions: inhibitor of dihydrofolate
reductase/folic acid metabolism and reducing inflammation by elevation of
extracellular adenosine (ADO). Tregs are regulatory T cells responsible for
keeping the immune system in check by suppressive activation and proliferation
of wide variety of cell types. One of the mechanisms through which Treg
suppress other cells is through production of extracellular ADO by CD39/CD73,
expressed on the surface of Tregs. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Given that the MTX also exerts its effect through generation
of ADO by CD39/CD73 and that CD39/CD73 are also important in Tregs activity,
the authors investigated possible link between MTX unresponsiveness and expression
of CD39 on Tregs in RA patients. The authors first observed that parameters
related to disease severity were significantly higher in UR-MTX patients than
in R-MTX (responsive) patients. Furthermore, the number of circulating Tregs
was lower in UR-MTX than in R-MTX. Encouraged by these findings, the
researchers compared expression of CD39 and CD73 on Tregs from R-MTX and UR-MTX
RA patients. The expression of CD39 on Trges from UR-MTX RA patients was
significantly lower than that in R-MTX patients. To find out if the increase in
number of CD39+Tregs in R-MTX was a result of MTX treatment, the authors
followed some patients and studied CD39+ expression on T regs before and after
treatment. Although there was no difference in percentage of CD39+ tregs in R
and UR-MTX before treatment, their numbers increased much more in R-MTX
patients than in UR-MTX patients following treatment. They further observed
that the density of expression of CD39 was low in UR-MTX patients before and
after treatment in comparison to R-MTX patients. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<!--[if gte mso 9]><xml>
<o:DocumentProperties>
<o:Revision>0</o:Revision>
<o:TotalTime>0</o:TotalTime>
<o:Pages>1</o:Pages>
<o:Words>435</o:Words>
<o:Characters>2485</o:Characters>
<o:Company>UCSF</o:Company>
<o:Lines>20</o:Lines>
<o:Paragraphs>5</o:Paragraphs>
<o:CharactersWithSpaces>2915</o:CharactersWithSpaces>
<o:Version>14.0</o:Version>
</o:DocumentProperties>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>JA</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
<w:UseFELayout/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="276">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;}
</style>
<![endif]-->
<!--StartFragment-->
<!--EndFragment--><br />
<div class="MsoNormal">
Various attempts have been made in the past to identify a
biomarker for MTX unresponsiveness. This study provides a unique non-invasive approach
of using CD39 expression on Tregs as biomarker for unresponsiveness. <o:p></o:p></div>
</div>
rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-15692600127482021602015-01-27T15:08:00.001-08:002015-01-27T15:14:26.452-08:00How do vaccines interact with human cells? <div dir="ltr" style="text-align: left;" trbidi="on">
<div class="Publishwithline">
<br /></div>
<div class="MsoNormal">
In a recently published study, scientists have identified various
transcriptional programs induced in human antigen presenting cells (APCs) by
various vaccines. The article published in <a href="http://www.nature.com/ncomms/2014/141022/ncomms6283/full/ncomms6283.html">October
issue of Nature Communications</a> sheds new light on the mechanisms of vaccine
interaction with human dendritic cells (DCs), a primary APC involved in vaccination
response. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Previous studies have shown that vaccination mostly depend
on dendritic cells. DCs are highly efficient in presentation of antigen. In
response to a pathogen, DCs transcribe various set of genes that then interact with
each other. Although, many sub-populations of DCs have been identified in human
blood, skin and other tissues, the role of these populations in eliciting specific
immune response to different vaccines is not entirely known. Furthermore, it is
not much known about the various transcriptional programs initiated in response
to different vaccines.<o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Romain Banchereau and colleagues from Baylor Institute for Immunology
Research, Dallas and Jackson Laboratory for Genomic Medicine, Farmington used a
unique multi-step approach to understand how human DCs respond to vaccine challenge
in vitro. They studied transcriptional changes in DCs that were first generated
by culturing monocytes (a precursor to DC) with different cytokines and then exposing
them to a number of pathogens. The researchers observed a broad spectrum of
unique and common transcriptional responses to pathogens over time. To further
understand the biological significance of these transcriptional responses, the
scientists generated a framework that groups transcripts into modules based on
their co-expression across pathogens, time points, and DCs. They found that
modules represented alteration of many biological pathways including interferon
response, inflammation, antigen processing and presentation, DC maturation and
T cell activation.<o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<w:sdt contentlocked="t" id="89512093" sdtgroup="t"><span style="font-family: "Calibri","sans-serif"; font-size: 1.0pt; mso-ansi-language: EN-US; mso-ascii-theme-font: minor-latin; mso-bidi-font-family: "Times New Roman"; mso-bidi-language: AR-SA; mso-bidi-theme-font: minor-bidi; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin;"><w:sdtpr></w:sdtpr><w:sdt docpart="72D99BFC17124B2D8D57CAE80DFDEC49" id="89512082" storeitemid="X_3B3421CB-D2C3-4828-9769-09DAA5407D0A" text="t" title="Post Title" xpath="/ns0:BlogPostInfo/ns0:PostTitle"></w:sdt></span>
</w:sdt>
<br />
<div class="MsoNormal">
The investigators then applied the same approach to study
transcriptional responses of various APCs to 13 commercially available vaccines
in vitro and observed that response to different vaccine was mediated through
unique APC subsets. In a further effort to understand the differences in immune
pathways required for vaccination to those that are responsible for
pathogenesis of a particular disease, the scientists applied the same framework
to analyze transcriptional profile of individuals vaccinated with influenza
vaccine and individuals with asymptomatic and symptomatic influenza infections.
They found that vaccinated individuals showed similar transcriptional profiles
to asymptomatic individuals and both showed a mild signature. In contrast, symptomatic
individuals showed strong response. The researchers acknowledge that this
approach can help in identifying which pathways are require for vaccination and
which for establishing infection and this distinction between two pathways can
help in development of safer and more effective vaccines in future.<o:p></o:p><br />
<br />
Overall, this study provides a good understanding of transcriptional response of DCs to current vaccines and will certainly add in development of next generation vaccines, in which specific sub-populations of APCs can be targeted for a more effective response to a particular pathogen.</div>
</div>
rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-24169738461186407982015-01-21T12:44:00.002-08:002015-01-27T15:05:35.407-08:00LL37 identified as an auto antigen in Psoriasis<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: left;">
<span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif;"><span style="background-color: white;">According a new study published in nature
communications, anti-microbial peptide (AMP) LL37 acts as an auto antigen in psoriasis.
The study shows that LL37 was recognized as an antigen by circulating T cells
in 46% of psoriatic patients. This recognition was shown by proliferation of T
cells and production of interferon gamma in response to LL37. None of the
controls showed such response.</span></span></div>
<div style="text-align: left;">
<span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif;"><span style="background-color: white;"><br /></span><span style="background: white;">Roberto
Lande and colleagues from Italy and Switzerland published their findings in <a href="http://www.nature.com/ncomms/2014/141203/ncomms6621/full/ncomms6621.html">December
issue of Nature communications</a>. They performed their research using
blood from psoriasis patients.</span></span></div>
<div style="text-align: left;">
<span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif;"><span style="background: white;"><br /></span><span style="background-color: white;">Psoriasis is a common condition of skin
characterized by development of red scaly plaques on skin. Although it is
sometimes considered an autoimmune disease, the nature of the auto antigen that
leads to development of auto reactive T cells is not known.</span> LL37 is an
AMP that has been shown to be overexpressed in psoriatic skin and play
important roles in pathogenesis of psoriasis. It forms complexes with extracellular
self-nucleic acid. These complexes then activate plasmatoid and myeloid DCs which
in turn leads to activation of T helper cells. This process then starts an
inflammatory cascade. However, it was not known if LL37 can directly serve as
an auto-antigen and stimulate T cells.</span></div>
<div style="text-align: left;">
<span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif;"><br /><span style="background-color: white;">In this study, the authors established that
psoriatic T cells were specifically responding to LL37 by showing that T cells
respond only to LL37 when stimulated with a variety of other AMPs.</span> The
authors also looked at correlation of response to LL37 and disease status and
found that up to 75% of psoriatic patients with moderate to severe plaque
psoriasis and with a Psoriasis Activity Severity Index (PASI) score of more
than 10 responded to LL37. <span style="background: white;">The
LL37 specific T cells in psoriasis patients showed production of pathogenic
cytokines including IL17 as well as showed direct chemo tactic activity for
inflammatory cells and cytotoxic ability. The study also showed that these T
cells possess the ability to migrate into psoriatic skin lesions. This was
further validated by finding of LL37 specific cell from skin biopsy of a
psoriatic patient who earlier showed positive response of blood T cells to LL37.</span></span></div>
<div style="text-align: left;">
<span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif;"><span style="background: white;"><br /></span><o:p></o:p></span></div>
<div style="text-align: left;">
<span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif;"><span style="background-color: white;">In conclusion, this study shows that LL37 is an
auto antigen in psoriasis and could be an appealing target to treat psoriasis.</span></span></div>
<br />
<div class="MsoNormal">
<o:p></o:p></div>
<div class="MsoNormal">
<span style="color: #222222; font-family: "Arial","sans-serif"; font-size: 10.0pt;">
<!--[if !supportLineBreakNewLine]-->
<!--[endif]--><span style="background: white;"><o:p></o:p></span></span></div>
<div class="MsoNormal">
<o:p></o:p></div>
</div>
rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-6333241218628101542014-12-04T16:48:00.001-08:002014-12-04T16:48:21.322-08:00Link between placental microbiome and pre-term birth<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal">
According to a recently published study in <a href="http://stm.sciencemag.org/content/6/237/237ra65.full#title18">Science
translation medicine</a>, the placental microbiome might be associated with
pre-term birth less than 37 weeks, and a remote history of antenatal infection in the
first trimester. In this study, which was based on placental collection from
320 subjects, the investigators analyzed the human placental microbiome and
provided details on microorganisms present, their probable functions and
overall structure of placental microbial community.<o:p></o:p></div>
<div class="MsoNormal">
Due to recent advances in sequencing technologies, a large
number of studies have looked at the structure, function and diversity of human
microbiome across multiple body sites in both healthy and disease states.
Studies conducted on newborn babies have shown that the gut microbiome of
neonates show complex microbial communities in the first few weeks of life.
However, the source of these microbes and the time at which the infants acquire
those is not yet known. It has also been shown that gut microbiome of full-term
infants is different from that of low birth weight infants during the first few
weeks of life, indicating that the infants might acquire these microbes in
utero through a common source and that the composition of the microbiome might
change with length of gestation. The authors of this study hypothesized that
the human placenta could be that source. <o:p></o:p></div>
<div class="MsoNormal">
The investigators of this study used whole-genome shotgun
(WGS), a technique involving sequencing long strands of DNA, to determine the
taxonomic classification of placental microbiome. They noted that several
species of oral microbiome were detected in the placenta. These included <i>Prevotella tannerae</i> and non-pathogenic <i>Neisseria</i> species. They also found high
abundance of <i>E. coli</i> in most
individuals. The authors further compared the microbial community observed in
placenta with those reported from other body sites (oral, stool, skin, nasal
and vaginal) from non-pregnant healthy subjects using publicly available HMP
(Human Microbiome Project) data. They observed that placental microbiota showed
similarity to oral phyla only. Furthermore, the relative abundance of metabolic
pathways was different in placenta when compared to other body sites. For
example, the metabolism of co-factors and vitamins showed a greater relative
abundance in placental functional gene profile.<o:p></o:p></div>
<div class="MsoNormal">
The authors found a statistically significantly association
between placental microbiome and pre-term birth less than 37 weeks. The researchers
also identified various placental taxa whose abundance was enriched or
diminished among women who experienced pre-term births. They also observed a
statistically significant association between placental microbial community and
a remote history of antepartum infection. <i>Streptococcus
and Acinetobacter</i> were found to be enriched in women with a remote history
of antepartum infection.<o:p></o:p></div>
<div class="MsoNormal">
In conclusion, Aagaard and colleagues show that in contrast
to the widespread believe that intra-uterine environment is sterile, human
placenta harbors a variety of non-pathogenic commensal species, and the overall
microbiome profile of placenta is most similar to that of non-pregnant human
oral cavity. They also observed correlation between placental microbiome and
pre-term birth and a history of antenatal infection. <o:p></o:p></div>
<div class="MsoNormal">
The authors also noted several limitations of the study. The
authors compared the placental microbiome with microbiome of other body sites
from non-pregnant subjects. Moreover, the authors were not able to characterize
the placental microbiome in early preterm gestation in women who had a full
term delivery. Still, the study presents some interesting findings and
indicates towards an essential role of placental microbiota in human pregnancy.
<o:p></o:p></div>
<br />
<div class="MsoNormal">
<br /></div>
</div>
rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-71111899773501209352012-09-02T18:21:00.002-07:002015-01-26T11:23:33.644-08:00An interesting paper on HERVs<div dir="ltr" style="text-align: left;" trbidi="on">
<div dir="ltr" style="text-align: left;" trbidi="on">
<!--[if gte mso 9]><xml>
<o:DocumentProperties>
<o:Template>Normal.dotm</o:Template>
<o:Revision>0</o:Revision>
<o:TotalTime>0</o:TotalTime>
<o:Pages>1</o:Pages>
<o:Words>512</o:Words>
<o:Characters>2919</o:Characters>
<o:Company>UBC</o:Company>
<o:Lines>24</o:Lines>
<o:Paragraphs>5</o:Paragraphs>
<o:CharactersWithSpaces>3584</o:CharactersWithSpaces>
<o:Version>12.0</o:Version>
</o:DocumentProperties>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:Zoom>0</w:Zoom>
<w:TrackMoves>false</w:TrackMoves>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:DrawingGridHorizontalSpacing>18 pt</w:DrawingGridHorizontalSpacing>
<w:DrawingGridVerticalSpacing>18 pt</w:DrawingGridVerticalSpacing>
<w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery>
<w:DisplayVerticalDrawingGridEvery>0</w:DisplayVerticalDrawingGridEvery>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:DontGrowAutofit/>
<w:DontAutofitConstrainedTables/>
<w:DontVertAlignInTxbx/>
</w:Compatibility>
</w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" LatentStyleCount="276">
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin-top:0cm;
mso-para-margin-right:0cm;
mso-para-margin-bottom:10.0pt;
mso-para-margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"Times New Roman";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;}
</style>
<![endif]-->
<!--StartFragment-->
<br />
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<br />
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;">
<b><span style="font-family: 'Times New Roman', serif; font-size: 13.5pt;">Expression of Human Endogenous Retrovirus Type K
Envelope Protein is a Novel Candidate Prognostic Marker for Human Breast Cancer</span></b><span style="font-family: 'Times New Roman', serif; font-size: 13.5pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;">
<span style="font-family: inherit;">I recently happened to read an interesting short
report published in August 2011 issue of <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352153/">Genes and Cancer</a>.
In this study, the authors evaluated the use of expression of envelope (env)
protein of human endogenous retroviruses-K (HERV-K) as a prognostic marker of
breast cancer. HERVs constitute about 8% of human genome. There are many
distinct families of HERVs present in human genome. Most of these families are
defective and could not encode complete viruses. However, HERV-K family shows a
conservation of seemingly intact retroviral genes as it is one of the most
recently integrated viruses. In a previously conducted study, the
authors observed the expression of HERV-K env mRNA and protein in breast cancer
tissues obtained from US women. To further study the role of HERV-K env mRNA as
a prognostic marker for breast cancer, the authors looked at expression of
HERV-K env mRNA and protein in breast cancer tissues obtained from both Chinese
and US women. The authors also analyzed the relationship between HERV-K env
expression and disease severity in these women.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;">
<span style="font-family: inherit;"><br /></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;">
<span style="font-family: inherit;">Methodology and Results:<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;">
<span style="font-family: inherit;">One hundred and twenty tissues from Chinese
women including 40 breast cancer tissues, 40 matched adjacent uninvolved breast
tissues and 40 breast tissues from benign breast diseases but not cancer were
used in this study. HERV-K env mRNA was detected in 70% of breast cancer
samples and 20% of surrounding uninvolved tissues from breast cancer patients.
No HERV-K env mRNA was detected in breast tissues from control patients.
Similar to mRNA results, HERV-K env protein expression was also higher in
cancer tissues in comparison to controls. The authors also found medium to
strong expression of env protein in cancerous tissues and weak to no expression
in adjacent non-cancerous tissues.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;">
<span style="font-family: inherit;">The authors then looked at relationship between
expression level of HERV-K protein and clinical features of the patients. 82%
of the patients with high expression of HERV-K in their tumor had a tumor size
greater than 3 cm. HERV-K env expression also correlated with other clinical
and pathological characteristics in these patients. Furthermore, the scientists
conducted a Kaplan-Meier survival analysis and found that the patients with
high expression of HERV-K env protein had a significantly shorter overall
survival in comparison with patients with moderate to low HERV-K env protein expression.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;">
<span style="font-family: inherit;"><br /></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;">
<span style="font-family: inherit;">Taken together, all these results indicate that
HERV-K env protein expression is highly upregulated in human breast cancer
tissues and not in adjacent non-cancerous tissues or normal breast tissues.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;">
<span style="font-family: inherit;">In all the paper is nicely written and all the
experiments seems to be nicely conducted. However, this paper exclusively talks
about env but what about pol and gag? Expression of pol is particularly
important as pol encodes for reverse transcriptase, which is required for
production of new virus progenies. <o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;">
<span style="font-family: inherit;">The study did not observe any association
between HERV-K env expression and ER/PR status. These results were surprising
as earlier studies have observed that expression of HERV-K mRNA and protein was
higher in breast cancer cell lines treated with estradiol and progesterone than
in cells without treatment<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-family: inherit;"><br /></span></div>
<div class="MsoNormal">
<br /></div>
</div>
</div>
<!--EndFragment--></div>
rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-86400521752298156072012-04-25T13:22:00.000-07:002012-04-25T13:22:24.346-07:00Preterm infants' T cell responses to inactivated Poliovirus vaccine<div dir="ltr" style="text-align: left;" trbidi="on">
I am writing a new blog after a long long time. Well, what a better way to start than this article published in 2009 issue of JID. http://jid.oxfordjournals.org/content/201/2/214.long<br />
<br />
<b>Background:</b>
Preterm infants are more susceptible to infection as their immune system is immature.
earlier studies have examined humoral immune responses to many viral and bacterial vaccines in preterm infants. These studies have found disparity in antibody production between preterm and term infants.
However, not much is known about T cell response to these vaccines in preterm infants. Since, adequate antibody production depends upon T cell help to B cells, the disparities in antibody production may reflect disparity in T cell responses in these two groups.<br />
In the present study, the authors recruited 33 preterm and 50 term infants and studies their T cell response to vaccines.<br />
<br />
<b>Results:</b>
Of the 33 preterm infants, final results were available for 27 infants and of the 50 term infants, final results were available for 35 infants.
First, the authors looked at the frequency of circulating CD4+ T cells in these two groups at 2 months and 7 months of age. There was no change in the frequency at these two time periods. Next, the authors looked at memory Cd4+ cells (Cd4+CD45RO+) in these infants. They observed that 7 month old preterm infants had fewer memory cells than seven month old term infants.<br />
Furthermore, the authors stimulated CD4+ cells from both set of infants with Staphylococcus entertoxin B, Sabin Oral polio vaccine, serotype 3 strain and uninfected vero cell lysate by culturing whole blood with these in the presence of costimulatory monoclonal antibodies to CD28 and CD49d. Then they looked for percentage of CD4+ cells positive for CD69 and IFN-g.
In response to stimulation with SEB, preterm infants had lower frequency of CD4+CD69+IFN-g+ cells than did term infants at 2 and seven months of age.
The authors then compared the frequency of CD69+ and IFN-g+ cells among CD4 and CD45RO cells in both group of infants before and after vaccination with OPV serotype 3. Both the groups of infants developed a significant increase in poliovirus specific Cd69+IFg+ cells relative to prevaccination responses.<br />
When the authors compared the CD69+ IFN-g+ responses between preterm and term infants after vaccination, they observed that frequency of CD4+CD69+, CD4+CD69+IFN-g+, CD4+CD45RO+CD69+ and CD4+CD45RO+CD69+IFN-g+ cells was comparable in two groups.
To evaluate cell mediated immunity, PBMCs were isolated from both groups of infants (pre and post vaccination) and stimulated with OPV serotype 3. A positive proliferative response was defined as stimulation index of 3. It was observed that mean poliovirus-type 3 specific proliferation after vaccination was significantly lower in preterm infants than in term infants.<br />
The authors next looked at neutralizing antibody response to all three subtypes of poliovirus in the sera of these infants after vaccination. All the infants showed neutralizing anitbodies post vaccination. There was no significant difference in geometric mean titer (GMT) to serotype 2 and 3 in the two groups of infants. However, GMT to serotype 1 was significantly low in preterm infants.
To compare the safety of this vaccine in preterm and term infants, the authors looked for medically attended events (MAE) in both groups for 30 days. There were no significant events.<br />
<br />
<b>Discussion:</b>
The present study establishes that preterm infants, similar to term infants, generate a poliovirus type 3–specific T cell response and that the frequency of circulating poliovirus-specific responder T cells is comparable between preterm and term infants.<br />
The study however, detected differences in circulating T cell populations between term and preterm infants.
</div>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com1tag:blogger.com,1999:blog-1418032058537849255.post-57567750489514054412011-04-02T18:47:00.000-07:002011-04-02T18:50:57.037-07:00Function of miR-146a in controlling Treg cell mediated regulation of Th1 responsesFunction of miR-146a in controlling Treg cell mediated regulation of Th1 responses<br />I recently had the pleasure of listening an interesting talk on the function of micro RNAs in controlling the function of Tregs. The presenter was Dr. Li-Fan Lu from Howard Hughes Medical Institute and Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY. Presented here is a brief blog on one of his paper.<br />Regulatory T cells (Tregs) have a suppressive function in body. They limit “collateral damage” resulting from protective immunity to infection and suppress sterile inflammation as well as unwanted immune responses to “self” and allergens. Tregs express FoxP3, an X chromosome encoded transcription factor which plays an important role in differentiation, homeostasis and function of Treg cells. It has been observed that FoxP3 directly or indirectly controls several thousand genes in Tregs. These genes are called as FoxP3 amplified genes many genes that serve as hallmark of Tregs and play important roles in their homeostasis and function. Also included among the FoxP3 amplified genes are those that code for noncoding RNAs called micro RNA (miRNA). These miRNAs serve as important regulators of Treg homeostasis and function both in basal and inflammatory settings. One such miRNA is miRNA-155, the cancer associated miRNA, which is constitutively expressed in high amounts in Treg cells in a FoxP3 dependent manner. It is transiently upregulated in T cells lacking FoxP3, B cells and myeloid cells up on activation. The investigators of this paper have previously shown that miR-155 causes increased response in Tregs to their key survival and growth molecule, IL-2 and is thus responsible for maintaining the numbers of Tregs. Another miRNA constitutively expressed in high amounts in Tregs is miR-146a. Like miR-155, it is induced up on activation of effector T cells and myeloid cells. In the present paper the authors tend to determine the role of miR-146a in Tregs. Their results are as follows:<br />• Elevated miR-146a expression in Tregs: <br />miRNA expressions were compared among FoxP3+ Treg cells and FoxP3- non Treg CD4+ cells---miR-146a was more expressed in Tregs in comparison to non-Tregs.<br />• miR-146a deficiency resulted in increased numbers but impaired function of Tregs:<br />Firstly, the authors examined FoxP3+ Treg cell subsets in the thymus and in the peripheral lymphoid organs of miR-146a deficient mice. They observed comparable sizes of different thymocyte and peripheral lymphoid and myeloid cell subsets and similar T cell activation status among the wild type and mutant mice. The number of FoxP3+ Tregs in mutant mice was higher in the periphery (but not in thymus) in comparison to wild type mice. These FoxP3+ Tregs also showed heightened proliferative activity as shown by increased expression of Ki67 and increase in other activation markers. <br />In next set of experiments, the authors transferred mixed bone marrow (1:1ratio of miR 146a deficient or sufficient Tregs mixed with Ly5.1 B6 or Ly5.1 FOXP3 KO) into Rag2-/- (or TCRβδ -/-) mice. They observed that in the mice group Mirn 146a-/-/FOXP3 KO, 40% of the mice died before the day of analysis. In these mice, all Tregs lack mir 146a as FOXP3 KO BM cells fail to generate Tregs; all other BM derived cells originate from both miR 146a deficient and sufficient BMs. The purpose of these experiments was to generate a miR 146a sufficient environment and then study the function of miR146a deficient Tregs in that environment. These mice showed severe clinical conditions and only 40% survived. Histologicaly also, these mice showed massive lymphocyte activation and tissue infiltraion. In contrast, mir 146a-/-/B6 mice had both miR 146a deficient and sufficient Tregs and they showed no clinical or histological signs of immune mediated lesions. So what was the cause of the adverse clinical and histological conditions in the mir 146a-/-/FOXP3 KO mice? The authors observed that the cause of these effects was not due to decrease in number of Tregs as the number of Tregs in KO mice was actually more than in control mice (mir 146a +/+/FOXP3 KO). The mir 146a -/-/ B6 mouse also showed an increase in miR 146a deficient Tregs than in controls (mir 146+/+/B6). These results suggested that miR146a deficiency increases the number of Tregs. <br />The authors next studied the activation of miR 146a sufficient T effector cells and observed a highly proliferative activity (Ki67), an increased CD62L low cell subset and high levels of activation markers ICOS and CTLA4 in FOXP 3 KO mice. However, both miR 146a deficient or sufficient cells showed control activation in a miR 146 a sufficient environment (B6 Ly5.1+ MICE). These results suggest that miR146 a play an important role in Treg mediated immunological tolerance.<br /><br />• miR-146a deficiency in Treg cells resulted in dysregulated IFNγ responses: In the next set of experiments the authors isolated miR-146a deficient or sufficient Tregs from mir 146a-/-/B6 or mir146a-/-/FOXP3 KO mice and co-cultured them with wild type responder CD4+ T cells (in the presence of CD3 antibody and irradiated T cell depleted splenocytes). They observed that miR 146a deficient Tregs from mir 146a-/-/B6 mice were as suppressive as miR 146a sufficient Tregs from control animals (mir146a+/+/B6). However, miR 146a deficient Tregs from knock-outs were more suppressive than miR146a sufficient Tregs from controls. These results indicate that deficiency of miR 146a did not diminish the overall suppressive activity of Tregs. They also observed that loss of miR146a in Tregs resulted in increase production of pro-inflammatory cytokine IFNγ by both miR 146a sufficient and deficient Cd4 and CD8 cells. This increase was not observed in the presence of miR146a sufficient Tregs.<br /><br />• IFNγ blockade prevents the autoimmune disease in mice harboring miR-146a deficient Tregs: The next question was weather this increased production of IFNγ is responsible for clinical condition in Mirn 146a-/-/FOXP3 KO mice. To answer this question, the investigators performed experiments in which IFNγ was blocked by treating these mice with IFNγ blocking antibody. The increase in number of miR 146a deficient Tregs was not affected in the presence of blocking antibody. However, the blocking of IFNγ prevented disease in deficient mice. The blockade of IFNγ with blocking antibody did not cause simultaneous increase in IL4 and IL-17 (Th2 responses). These results suggest that the diseases observed in the miR146a deficient Tregs was IFN-gamma dependent and blockade of IFN-gamma can control Th2 and Th17 responses but not Th1 response.<br /><br />• miR 146a regulates stat1 in Tregs: Stat 1 is a key transcription factor downstream of IFN-gamma signaling. Thus, the authors transfected CD4+ T cells isolated from miR146a sufficient or deficient with a luciferase reporter construct containing wild type or mutant Stat1 and assessed luciferase activity. miR146a sufficient T but not deficient cells transfected with wild type Stat1 showed suppression of reporter activity. The authors also performed immunoblot analysis of Stat1 protein in Tregs and non-Tregs. There was an increase in production of Stat1 in Mir146a deficient Tregs and non-Tregs. <br /><br />• miR 146a controls Treg cell mediated regulation of IFNγ responses through targeting Stat1: Based on previous experiments the authors hypothesized that miR146a deficiency causes dysregulated IFN-gamma production, which in turn causes increased expression of Stat1, which can then lead to failure of Tregs to control Th1 response. To test this hypothesis, the authors generated miR146a deficient mice harboring a single function stat1 allele (Mirn 146a-/-/Stat1+/-). The BM cells from these mice were mixed with Ly5.1+ FOXP3 KO mice and transferred into Rag2-/- mice. Thus, the recipients are Mirn 146a-/-/Stat1+/-/FOXP3 KO. Then they measured the amount of Stat1 phosphorylated in Tregs and non-Tregs from these and from control mice (Mirn 146a-/-/Stat1+/+/FOXP3 KO). Both Tregs and non-Tregs from test mice showed nearly 50% reduction in phosphorylated stat1 in comparison to controls. The test mice also developed a much milder and delayed disease. The authors also observed significant reduction in production of IFN-gamma in tests mice<br /><br />Source: Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, Yoshimura A, Baltimore D, Rudensky AY. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010 Sep 17;142(6):914-29. PubMed PMID: 20850013; PubMed Central PMCID: PMC3049116.rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com1tag:blogger.com,1999:blog-1418032058537849255.post-45886520233431701582011-03-13T18:00:00.001-07:002011-03-13T18:00:51.786-07:00Viral danger signal control CD1d de novo synthesis and NKT cell activationViral danger signal control CD1d de novo synthesis and NKT cell activation<br /><br /><br />Source: Raftery MJ, Winau F, Giese T, Kaufmann SH, Schaible UE, Schönrich G. <br />Viralndanger signals control CD1d de novo synthesis and NKT cell activation. <br />Eur J Immunol. 2008 Mar;38(3):668-79. PubMed PMID: 18253929.<br /><br />Results:<br />1. Effect of IFNs on CD1D transcripts: Untreated DCs were treated with interferons. It was observed that type I IFN (IFN alpha) up regulates the number of CD1D transcripts. In contrast to this, IFN-gamma had no effect where as TNF-alpha down regulates the amount of CD1D transcripts. In another set of experiments, the authors found that IFN-alpha and beta diminished CD1A and CD1B mRNA in a dose dependent manner. In addition, they increased the levels of CD1D mRNA transcripts. Taken together these data indicate that type I IFN (signature cytokines of innate anti-viral immune response) enhance the expression of CD1D mRNA in human DC. <br />2. Differential regulation of CD1 expression in human DC exposed to TLR ligands: The authors next exposed DCs to various TLR ligands (Zymosan, TLR2; LPS, TLR4; Imiquimod, TLR7; CpG, TLR9) and looked for expression of CD1 genes. They observed that all TLR ligands reduced the amount of group 1 CD1 (A to C) transcripts and group 3 CD1 (E) transcripts. The only exception was CpG (TLR9 ligand) which did not cause any change in expression as TLR9 is not expressed in myeloid DCs. In contrast to group 1 and 3 CD1 molecules, group 2 CD1 molecules (CD1D) was upregulated by TLR7 ligand (Imoquimod, viral) and downregulated by TLR4 ligand LPS. These results indicate that CD1D is upregulated in response to viral pathogen associated molecular patterns in myeloid DCs.<br />3. Effect of viral infection on level of CD1D transcripts: The authors next infected immature DCs with virus (CMV or HSV-1). They observed that the number of CD1D transcripts was drastically enhanced in virus infected DCs. The other CD1 molecules were downregulated in response to infection. These results suggest that in response to virus infection, myeloid DCs downregulate group 1 and group 3 CD1 genes and upregulates expression of CD1D.<br />4. Effect of viral danger signals on CD1d protein: The investigators treated the UV-inactivated HSV-1, IFN-alpha, - beta, -gamma and imiquimod and investigated the surface expression of CD1 molecules and CD83, a marker for maturation of DCs by FACS. They observed that the surface expression of CD1d molecules was enhanced in presence of HSV-1 or type 1 IFN in comparison to untreated DCs. They also observed similar results with Western blot analysis. The DCs secreted type I IFN in response to UV-inactivated HSV-1. These results indicated that human myeloid DCs synthesize CD1d molecules induced by IFN-alpha in response to viral danger signals. <br />5. Effect of viral danger signal on NKT cells: As invariant NKT cells recognized only molecules presented by CD1d, the authors next investigated the effect of upregulation of CD1d molecules on DCs on NKT cells. Thus, they treated PBMCs with alpha-GalCer or UV-inactivated HSV-1. They looked for CD4+ NKT cells and IFN-gamma secretion and observed an increase in percentage of IFN-gamma secreting CD4+ NKT cells in virus treated cells compared to untreated ones. Blocking of CD1d caused reduction in NKT cells. These data indicate that activation and expansion of NKT cells in human PBMCs exposed to viral pathogen requires CD1d expressing cells.<br />6. What is the nature of NKT cell response, Th1 or Th2? Activated NKT cells secrete IFN-gamma, IL-4 and IL-10. The investigators observed that DCs treated with IFN-alpha, poly (I:C)(TLR3 ligand), imiquimod (TLR7) or UV inactivated HSV-1 could induce IFN-gamma secretion by NKT cells more efficiently than DCs treated with LPS (TLR4 ligand). Similar results were observed when IL-4 secretion was investigated. However, when IL-10 production was analyzed, it was observed that co-culture of DCs treated with virus or other signals with NKT cells caused reduced production of IL-10. Taken together these data indicate that DCs treated with viral danger signals cause NKT cells to induce a more Th1 like response in comparison to LPS treated DCs.rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-43522761865392594612010-12-30T05:31:00.001-08:002010-12-30T05:31:38.995-08:00Role of microbiota in evolution of adaptive immune system<span xmlns=''><p>Source: <span style='color:#333300; font-family:Times New Roman; font-size:13pt'>Science 24 December 2010: <br/>Vol. 330 no. 6012 pp. 1768-1773 <br/>DOI: 10.1126/science.1195568<br /></span></p><p><span style='color:#333333; font-family:Arial; font-size:13pt'><strong>Has the Microbiota Played a Critical Role in the Evolution of the Adaptive Immune System?<br /></strong></span></p><ol><li><div><a target='_blank' href='http://search?author1=Yun+Kyung+Lee&sortspec=date&submit=Submit'><span style='color:#333333; font-family:Times New Roman; font-size:9pt'><strong>Yun Kyung Lee</strong></span></a><span style='font-family:Times New Roman'><span style='color:#333333; font-size:9pt'><strong> and <a target='_blank' href='http://search?author1=Sarkis+K.+Mazmanian&sortspec=date&submit=Submit'>Sarkis K. Mazmanian</a></strong></span><span style='color:#2e6d8f; font-size:7pt; text-decoration:underline'><sup>*</sup></span><span style='color:#333333; font-size:9pt'><strong><br /> </strong></span></span></div><p><br /> </p></li></ol><ul><li>Microbes reside in several anatomical sites of human body including the skin, vagina, and mouth.<br /></li><li>Lower gastrointestinal tract of mammals harbor the greatest density and diversity of commensal microorganisms (including bacteria, archaea, fungi, viruses, protozoans, and helminthes.<br /></li><li>It has been observed that the development of gut associated lymphoid tissue (GALT), the first line of defense for the intestinal mucosa, is defective in germ free animals.<br /></li><li>It has also been observed that germ free mice display fewer and smaller Peyer's patches, smaller and less cellular mesenteric lymph nodes and less cellular lamina propia of small intestine relative to animals with a microbiota. Furthermore, these mice have been shown to exhibit reduced expression of TLRs and MHC class II molecules.<br /></li><li>Number of CD4+ T cells is also reduced in lamina propria of germ free mice. Development of isolated lymphoid follicles is also defective in the absence of microbes.<br /></li><li>Multiple proportions of intestinal immune cells require the microbiota for their development and function.<br /></li><li>In addition to its effect on intestinal immunity microbiota also effects extra intestinal immunity.<br /></li><li>It has also been observed that germ free mice are more susceptible to microorganisms like Shigella, Bacillus and Leishmania. Thus, in addition to development microbiota also effects functional aspects of intestinal and systemic immunity.<br /></li><li> Host mechanisms and the microbiota may have evolved to collaborate against infectious agents. <br /></li><li>Studies have shown an antagonistic relationship between microbiota and overt pathogens.<br /></li><li>Harnessing the immunomodulatory capabilities of microbiota may offer new avenues for development of antimicrobial therapies for infectious diseases.<br /></li><li>Microbiota play important roles in effector CD4+ T cell differentiation. During infection microbial and host signals provide cues to naïve CD4+ T cells to differentiate into various proinflammatory and anti-inflammatory subsets.<br /></li><li>Microbiota has been shown to affect the TH1-TH2 balance in the systemic immune compartments.<br /></li><li>Studies have shown that TH17 cell development in the gut is specifically affected by commensal bacteria.<br /></li><li>Of the various microbial species that constitute the microbiota of mice, only segmented filamentous bacteria (SFB) have been shown to direct intestinal T helper cell development. <br /></li><li>Researchers from around the world have proposed that life style changes have caused a fundamental alteration in the association of humans with the microbial world. The alteration in composition of healthy microbiota leading to altered microbial colonization is known as dysbiosis.<br /></li><li>Although it is not known yet whether dysbiosis causes any human diseases, it may affect autoimmunity by altering the balance between toleragenic and inflammatory members of the microbiota.<br /></li><li>In a healthy microbiome, there is an optimal proportion of both pro- and anti-inflammatory organisms (represented here by SFBs and B. fragilis), which provide signals to the developing immune system (controlled by the host genome), leading to a balance of Treg and TH17 cell activities. <br /></li><li>Altered community composition of the microbiome due to life-style, known as dysbiosis, may represent this disease-modifying component. An increase in proinflammatory microbes (for example, SFBs in animalmodels)may promote TH17 cell activity to increase and thus predispose genetically susceptible people to TH17-mediated autoimmunity.<br /></li><li>The imbalance between TH17 cells and Tregs ultimately leads to autoimmunity.<br /></li><li>We propose that certain microbes, such as SFBs, that can peacefully coexist with a healthy host but still retain pathogenic potential be termed "pathobionts" to distinguish them from opportunistic pathogens that are acquired from the environment and cause acute infections.<br /></li><li>The adaptive immune system distinguishes between self and foreign antigens and mounts an appropriate response to clear invading pathogens by recognizing non-self molecules. <br /></li><li>The adaptive immune system must either tolerate or ignore the microbiota.<br /></li><li>Several studies suggest that symbiotic bacteria have evolved the mechanisms to suppress unwanted inflammation toward the microbiota by actively inducing mucosal tolerance. <br /></li><li>The authors propose a model for co-evolution of adaptive immune system with the microbiota.<br /></li><li>According to this model, The adaptive immune system develops under the control of the vertebrate genome to produce various cell types. The evolutionarily ancient molecule TGFb directs the differentiation of Foxp3+ Treg cells.<br /></li><li>Over millennia of coevolution, commensal microbes (B. fragilis used as an example here) produced molecules that networked with the primordial immune systemto help expand various Treg cell subsets (for example, IL-10–producing Foxp3+ Treg cells).<br /></li><li>Pro-inflammatory pathobionts (such as SFBs) may have induced TH17 cell differentiation to increase mucosal defenses against enteric pathogens.<br /></li><li>The modern adaptive immune system may have arisen from two distinct events: Tregs and Th17 cell types evolved independently or through the sequential development of TH17 cells from Treg cell precursors. <br /></li><li><div>Taken together, the modulation of Tregs and TH17 cells by commensal microorganisms and pathobionts, respectively, appears to shape the immune status of the host and thus represents a possible risk factor for autoimmune diseases that appears to depend on balanced Treg-Th17 proportions.<br /></div><p style='margin-left: 36pt'><span style='font-family:Times New Roman; font-size:9pt'><br /> </span> </p></li></ul></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com1tag:blogger.com,1999:blog-1418032058537849255.post-7433304967236881052010-12-12T22:41:00.001-08:002010-12-12T22:41:02.200-08:00Loss of Th17 is associated with CD4 T activation in 2009 H1N1 patients<span xmlns=''><p><pre><code><span style='font-family:Calibri; font-size:11pt'><strong>Source:</strong> Jiang TJ, Zhang JY, Li WG, Xie YX, Zhang XW, Wang Y, Jin L, Wang FS, Zhao M.<br /></span></code></pre></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'>Preferential loss of Th17 cells is associated with CD4 T cell activation in<br /></span></code></pre></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'>patients with 2009 pandemic H1N1 swine-origin influenza A infection. Clin<br /></span></code></pre></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'>Immunol. 2010 Dec;137(3):303-10. Epub 2010 Oct 12. PubMed PMID: 20943443.<br /></span></code></pre></p><p><br /> </p><p> H1N1 swine-origin influenza A virus (S-OIV) is a novel influenza H1N1 strain that first emerged in humans in Mexico during March 2009. The incubation period is 1-7 days. Past studies have reported that host immune response can be a critical factor in determining various outcomes of influenza infection. These studies have reported that while moderate increase in proinflammatory responses may favor viral clearance, hyper activated inflammatory response can have detrimental effects on the host. It has also been noted that after innate immunity activation there could be an abundance of virus induced inflammatory cytokines which can lead to subsequent antigen non-specific T cell activation in mice and human with viral infection. <br /></p><p>Among the T cells, helper CD4+ T cells release a number of distinct cytokines. One such cytokine is IFN-gamma which is released by Th1 cells and which is conventionally thought to exacerbate tissue damage and control viral infection. Regulatory T cells (Tregs) are immunosuppressive and play an important role in the regulation of immune responses. In contrast, IL-17 producing CD4+ T cells (Th17) are known to play role in both chronic inflammation and in host defense against pathogens. Many studies have found that Th17 cells can play important role in protecting mice against influenza challenge. Studies have also observed Th1 and Th17 hypercytokinemia as early host response in severe pandemic influenza. <br /></p><p>In authors' words, "whether the change of T helper subsets could bridge the inflammatory activation and T cell activation during host-pathogen interactions at an early stage of A/H1N1 infection has not been well defined". <br /></p><p>Thus, in the present work, the authors tend to study peripheral T cells subsets in acute S-OIV-infected patients. <br /></p><p><strong>Study subjects:</strong> For this study, investigators collected blood samples from 53 confirmed S-OIV-infected patients and 21 healthy controls. The patients were divided into three groups according to the day of first clinical manifestation. These three groups included early stage group (Patients enrolled within 3 days after clinical onset of symptoms), intermediate stage group (patients enrolled between 4-7 days after onset) and late stage group (patients enrolled after 8 days).<br /></p><p><strong>RESULTS:<br /></strong></p><ol><li><strong>S-OIV infection results in generalized T cell depletion and T cell activation:</strong> Using flow cytometry the authors compared the absolute numbers of circulating CD3+, CD4+ and CD8+ T cells in 53 patients at the acute and convalescent stages of S-OIV infection. They observed that mean absolute CD3+, CD4+ and CD8+ T cell counts in healthy individuals were much higher than in patients. Among the three groups of patients, the patients in the early stage showed lowest counts and the counts progressively increased in intermediate and late stage patients. These data suggested that S-OIV infection leads to a rapid depletion of CD3+, CD4+ and CD8+ T cells at the early stage (1-3 days), followed by a rapid and significant restoration of CD3+, CD4+ and CD8+ T cells at 4 days after the onset of illness. Among the patients with early stage infection, T cell counts almost doubled in the convalescent phase. Among the intermediate stage patients, T cells counts were decreased at the convalescent stage and among the late stage patients no difference in T cell counts was observed in the convalescent phase. The authors also compared the expression of CD38 and HLA-DR on CD4+ and CD8+ T cells in different patient groups and healthy controls. They found that expression of CD38 and HLA-DR was higher in all CD4+ T cells than in healthy controls in early stage patients. Furthermore, they observed that expression of CD38 was upregulated in CD8+ T cells in early stage patients but there was no significant difference in HLA-DR expression on CD8+ T cells in early stage patients. The expression of CD38 and HLA-DR on CD4+ and CD8+ T cells gradually decreased in patients at the intermediate stage and late stage when compared to early stage patients. Interestingly, CD38 and HLA-DR expression were higher in convalescent stages among different groups. <br /></li><li><strong>Preferential loss of IL-17 expressing Th17 cells after S-OIV infection:</strong> The authors then compared the frequencies of Th1 (IFN-gamma producing CD4+ T cells), Th17 and Tregs in peripheral blood from healthy controls and patients and observed that the absolute T cell counts of Th1, Th17 and Tregs cells were significantly decreased in patients in comparison to controls. They also observed that percentage of Th1 cells was significantly increased in S-OIV infected patients in comparison to controls. They further observed that percentage of Th1 cells was more at the convalescent phase in early stage patients. All these data indicate that Th1 cells play important roles in viral clearance. In contrast to Th1 cells, the frequency of Th17 cells was significantly reduced in S-OIV infected patients in comparison to controls. However, the Th17 cells showed a gradual increase from early to late phase. Tregs did not show any significant difference in frequency among patients and controls. Thus, it can be derived that Th17 cells are more prone to be depleted at an early stage after S-OIV infection. <br /></li><li><strong>Th17 cells and CD4 depletion at early clinical onset is associated with sustained CD4 T cell immune activation:</strong> The authors next sought to determine the impact of depletion of Th17 cells and CD4 on T cell activation. They found that frequency of CD38+ T or HLA-DR+ T cells was negatively correlated with CD4 T cell counts or Th17 cell frequency. The authors did not observe any negative correlation with Th1 or Treg frequency. Taken together, all these data indicate that the CD4 depletion and selective loss of Th17 cells, not Th1 or Treg cells, were strongly associated with increased CD4+ T cell activation at the early stage of S-OIV infection. <br /></li><li><strong>S-OIV infection induced IFN-α constricts Th17 responses:</strong> The authors also analyzed the serum concentrations of IFN-α to examine its association with decrease of Th17 cells in virus infected patients. They found that serum IFN- α was highly upregulated in patients in comparison to controls. They also found that patients of early stage had lowest concentration of IL-17 among the three groups. To determine the effect of IFN- α on the production of IL-17 from Th17 cells in vitro, the authors treated PBMCs from healthy controls with IFN- α and looked for expression of IL-17 and IFN-λ. The experiment showed that IL-17 production from CD4+ T cells was significantly reduced in the presence of IFN- α. In contrast, the production of IFN-λ was significantly increased in the presence of IFN- α. These results indicate that S-OIV infection –induced IFN- α may partly constrict the function of Th17 cells. </li></ol></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-36043137622220390442010-12-05T23:32:00.001-08:002010-12-05T23:39:36.374-08:00Integral role of integrins in Th17 development<span xmlns=''><p><pre><code><span style='font-family:Calibri; font-size:11pt'><strong>Source: <br /></strong></span></code></pre></p><ul><li><pre><code><span style='font-family:Calibri; font-size:11pt'>Pociask DA, Kolls JK. Integral role of integrins in Th17 development. J <br /></span></code></pre></li></ul><p><pre><code><span style='font-family:Calibri; font-size:11pt'>Clin Invest. 2010 Dec 1;120(12):4185-7. doi: 10.1172/JCI45450. Epub 2010 <br /></span></code></pre></p><p style='margin-left: 18pt'><pre><code><span style='font-family:Calibri; font-size:11pt'>Nov 22. PubMed PMID: 21099101; PubMed Central PMCID: PMC2993609.<br /></span></code></pre></p><p style='margin-left: 18pt'><br /> </p><ul><li><pre><code><span style='font-family:Calibri; font-size:11pt'>Acharya M, et al. αv Integrin expression by DCs is required for Th17 cell <br /></span></code></pre></li></ul><p><pre><code><span style='font-family:Calibri; font-size:11pt'>differentiation and development of experimental autoimmune <br /></span></code></pre></p><p style='margin-left: 18pt'><pre><code><span style='font-family:Calibri; font-size:11pt'>encephalomyelitis in mice. <em>J Clin Invest.</em> 2010;120(12):4445–4452.<a name='12ca33e585528d32_B11'/><br /> </span></code></pre></p><p style='margin-left: 18pt'><br /> </p><ul><li><pre><code><span style='font-family:Calibri; font-size:11pt'>Melton AC, Bailey-Bucktrout SL, Travis MA, Fife BT, Bluestone JA, <br /></span></code></pre></li></ul><p><pre><code><span style='font-family:Calibri; font-size:11pt'>Sheppard D. Expression of αVβ8 integrin on dendritic cells regulates Th17 <br /></span></code></pre></p><p style='margin-left: 18pt'><pre><code><span style='font-family:Calibri; font-size:11pt'>cell development and experimental autoimmune encephalomyelitis in mice. <br /></span></code></pre></p><p style='margin-left: 18pt'><pre><code><span style='font-family:Calibri; font-size:11pt'><em>J Clin Invest.</em> 2010;120(12):4436–4444. <br /></span></code></pre></p><p><br /> </p><p>Th17 cells are a lineage of CD4+ T cells and are supposed to be derived by exposure of naïve CD4+ T cells to IL-6 and TGF-beta. They have been recently identified (2007). These cells secrete IL-17A and IL-17F as well as IL-21 and IL-22. Recent studies have shown that Th17 cells are critical for host defense against bacterial, fungal and viral infections at mucosal surfaces. In additions, Th17 cells have also been implicated in autoimmune diseases such as multiple sclerosis, psoriasis and rheumatoid arthritis. <span style='font-family:Courier New; font-size:10pt'><br /> </span></p><p>Several studies have shown that naïve CD4+ T cells differentiate into Tregs in the presence of TGF-beta. However they differentiate into Th17 cells in the presence of IL-6 and TGF-beta. TGF-beta is a multifunctional cytokine involved in many aspects of immunology, angiogenesis and epithelial growth as well as in pathogenic states such as fibrosis. TGF-beta is secreted from CD4+ T cells in an inactive form. In this form, TGF-beta is present in a complex with the latency associated peptide (LAP) through non-covalent bonds. Recent studies have shown that DCs can activate TGF-beta through integrins, suggesting that activation of TGF-beta occurs at the DC/T cell synapse. This activation of TGF-beta then drives the differentiation of Th17 T cells. <br /></p><p>Integrins are a family of heterodimeric cell surface receptors consisting of an alpha and a beta subunit. There are total 24 integrin subunits including 18 alpha and 6 beta. Five of these integrins share the αν subunit (ανβ1, ανβ3, ανβ5, ανβ6 and ανβ8) and can bind to the RGD tripeptide sequence on the LAP of TGF-beta. Two mechanisms have been proposed to explain integrin mediated activation of TGF-beta. According to first mechanism the binding of integrins, which are bound to the cytoskeleton such as integrin ανβ6, to the TGF-beta induces a conformational change upon the latent complex of TGF-beta. This conformational change allows the active portion of TGF-beta to be exposed to its receptor without breaking the TGF-beta/LAP bond. In the second mechanism proposed, integrin ανβ8, which lacks cytoskeleton attachment acts as an anchor for TGF-beta, allowing proteolysis by membrane bound MMP-14 (also known as mt1-MMP). <br /></p><p>Two recent papers have demonstrated the requirement of integrin ανβ8 activation of TGF-beta in the differentiation of Th17 cells (Acharya et al., 2010 and Melton et al., 2010). Both of these studies used experimental autoimmune encephalitis (EAE) diseases model. In this EAE diseases model, EAE was induced by immunization with MOG<sub>35–55</sub> peptide emulsified in CFA (containing <em>Mycobacterium tuberculosis</em> H37Ra). <br /></p><p>One of these studies considered the common requirement of TGF-beta in the development of Tregs and Th17 cells and found out that conditional knockout mice (αν-tie2 mice) that lack integrin αν on all hematopoietic cells have reduced proportions of Th17 cells in the lamina propria. When CD4+ T cells from these mice were treated with exogenous TGF-beta, they were able to differentiate into Th17 cells. The authors crossed mice with a floxed itgav allele (the allele that encodes αv) to LysM-cre, which allowed expression of αν integrins on lymphoid cells but not on macrophages and DCs. The authors showed that expression of αν integrins on LysM expressing cells was required for activation of TGF-beta, which is further required for Th17 cells generation in αν-tie2 mice. These results demonstrate the useful of αν in activation of TGF-beta and generation of Th17 cells. But, these data do not identify which αν integrins is responsible here. Mice lacking αν integrins are incapable of producing ανβ1, ανβ3, ανβ5, ανβ6 and ανβ8. So, any one of them can play a role in activation of TGF-beta.<br /></p><p>In another such recent study, the authors show similar reduction in number of Th17 cells in lamina propria of mice lacking ανβ8 expression on DCs (β8<sup>fl/fl</sup> × CD11c-cre mice). In both studies, mice did not develop experimental autoimmune encephalitis (EAE), a condition which is Th17 dependent. Both the studies looked at the cytokines involved in Th17 polarization. They found that there were no differences in IL-6, IL-23, TGF-beta expression after immunization for EAE. Both group of investigators showed that DCs were required to activate TGF-beta. When naïve CD4+ T cells were cultured in the presence of latent TGF-beta, they did not differentiate into Th17 cells unless DCs were also present in vitro. <br /></p><p>These two studies show a novel mechanism of development of Th17 cells. Th17 cells are important in autoimmune diseases and thus a lot of research has been going on to explore their generation. According to the mechanism proposed by these studies, naïve CD4+ t cells recognize antigens presented by DCs in MHC-classII dependent manner and also get induced to Th17 cells by activation of TGF-beta -through integrin ανβ8. One question that is still unanswered is how IL-17 is produced by gamma-delta T cells. A recent study has shown that Th17 differentiation can occur in the absence of TGF-beta signaling. They showed that IL-6, IL-23 and IL-1beta efficiently generated IL-17 production in naïve T cells independent of TGF-beta. All these studies are very important as they through light on Th17 differentiation. In order to develop therapeutic strategies for autoimmune diseases, it is critical to understand origin and development of Th17 cells.</p></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-6132325039858969662010-11-27T10:26:00.001-08:002010-11-27T10:26:07.590-08:00TLR3 ACTIVATION BY EBV-ENCODED SMALL RNA<span xmlns=''><p><span style='font-size:10pt'>Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T, Imai S, Fujieda M, Kawa K, Takada K. <br /></span></p><p><span style='font-size:10pt'>Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates <br /></span></p><p><span style='font-size:10pt'>signaling from Toll-like receptor 3. J Exp Med. 2009 Sep 28;206(10):2091-9. Epub 2009 Aug 31. <br /></span></p><p><span style='font-size:10pt'>PubMed PMID: 19720839; PubMed Central PMCID: PMC2757889.<br /></span></p><p><br /> </p><p>Epstein-Barr- virus encoded small RNA (EBER) is nonpolyadenylated, noncoding RNA that forms stem-loop structure by base pairing and giving rise to double-stranded RNA (dsRNA)-like molecules. EBER1 and EBER2 are 167 and 172 nucleotide long. EBER is the most abundant viral RNA in the latently infected cells. It binds to several cellular proteins including RNA activated protein kinase, ribosomal protein 22, lupus erythematosis-associated antigen and retinoic acid-inducible gene I. <br /></p><p>In this interesting article, the investigators found that EBER exists in the sera of patients with active EBV infection and induces type I IFN and inflammatory cytokines through TLR-3 mediated signaling. The authors postulate that this may account for the pathogenesis of active EBV infections that are characterized by cytokinemia. <br /></p><p><strong>RESULTS:<br /></strong></p><ul><li><div><strong>EBER is present in the culture supernatants of EBV-infected cells:</strong> The authors performed RT-PCR analysis of EBER1 in culture supernatants of Burkitt's lymphoma derived EBV-infected cell lines (Mutu+, Akata+) and EBV transformed lymphoblastoid cell lines (LCLs). They observed that EBER was detected at day 1 of culture and its expression increased and peaked on day 4. The release of EBER1 was higher than EBER2.<br /></div><p><br /> </p></li><li><div><strong>EBER induces signaling from TLR3: <br /></strong></div><ul><li>To investigate the role of EBER released from EBV infected cells, the authors first examined whether in vitro synthesized EBER1 could induce signaling from TLR3. They subjected total RNA from three LCL clones and EBV-infected and uninfected NU-GC-3 cells to RT PCR to detect TLR3. The results indicated that LCLs and gastric carcinoma NU-GC-3 cells expressed TLR3. <br /></li><li>The authors then added in vitro synthesized EBER1 into culture medium and found the induction of IFN-beta in LCLs and EBV positive and negative NU-GC-3 cells. The authors performed similar experiments using poly (I:C) instead of EBER and observed similar results. On performing ELISA, the authors observed that IFN-beta production was dependent on the amount of EBER1 that was added to the culture. <br /></li><li>Furthermore, when the authors pretreated LCLs with an anti-TLR3 antibody and then with EBER1, the expression of IFN-beta was markedly reduced as observed by both RT PCR and ELISA. <br /></li><li>The authors then looked for the effect of TLR-3 knockdown on EBER-1 induced IFN-beta production. For this, negative control siRNA or TLR-3-siRNA were transfected into EBER knockout-EBV infected AGS cells and after 48 hrs, these cells were treated with EBER1 or poly (I:C) and IFN-beta production was analyzed by RT PCR. TLR3 knockout caused reduced induction of IFN. These results indicated that EBER1 induces IFN through TLR3.<br /></li><li>IFN-regulatory factor 3 (IRF-3) and NF-kappa B function downstream of TLR3 signaling pathway. To analyze the effect of in vitro EBER1 on these downstream signals, the authors treated LCLs with in vitro synthesized EBER1 or poly(I:C) and cultured for 3 hrs after which they examined the phosphorylation of IRF3 and NF-kappa B by immunoblotting using antibodies against phosphorylated IRF3, total IRF3 and phosphorylated p65. They observed that both IRF-3 and NF-kappa B were phosphorylated upon treatment of the cells with EBER1 and poly(I:C). <br /></li><li><div>Now, the authors examined whether EBER1 that was released in the culture supernatant could induce the expression of IFN. EBV positive and EBV negative Mutu cells, EBV-positive and EBV-negative Akata cells, and EBV-negative Akata cells that were stably infected with EBER-positive EBV or EBER-knockout EBV were cultured for 4 days and then the culture supernatants were harvested. LCLs were treated with 1ml of these culture supernatants or with RNA extracted from 1ml culture supernatant. The RNA extracted from the LCLs was subjected to RT-PCR to detect IFN-beta. The results indicated that IFN was induced in EBV-positive cells but not in EBV-negative cells or EBER-knockout EBV-infected cells.<br /></div><p><br /> </p></li></ul></li><li><div><strong>EBER1 is detected as a complex with La in the culture supernatants, and the complex can induce TLR3 signaling:</strong> The previous results demonstrated that EER1 was stably present in the culture supernatants which meant that it must be bound by some proteins and thus is protected from degradation by nucleases. The investigators therefore examined whether EBER1 existed as a complex with EBER-binding cellular proteins in culture supernatants. They transfected Mutu+ cells with Flag-tagged La, L22 and PKR expression plasmids, cultured them for 48 hrs and detected La, L22 and PKR by immunoblotting of the cell lysates and immunoprecipitation of culture supernatants using anti-Flag antibody. They observed that although Flag-tagged L22, La and PKR were expressed equally in transfected cells, only La could be strongly immunoprecipitated from the culture supernatant. The authors then detected EBER1 in the immunoprecipitates using RT PCR. For this, RNA was extracted from the immunoprecipitates and subjected to RT-PCR to detect EBER1. The results showed that EBER1 was preferentially co-precipitated with La. The presence of La in the culture supernatants indicated that La was actively secreted from the living cells rather than passively released from dead cells. The results further suggested that EBER1 is released from EBV-infected cells as a complex with La. To further investigate whether EBER can activate TLR3 in complexes with La, they transfected EBER positive- and EBER knockout- EBV infected AGS cells with Flag-tagged La and cultured for 48 hrs. The culture supernatants were immunoprecipitated with anti-Flag antibody. Both these EBER+ and EBER- immunoprecipitates were added into the media of EBER-knockout EBV-infected AGS cells previously transfected with TLR3 siRNA (TLR3 knockdown) or with control siRNA. IFN-beta induction was analyzed by RT PCR. IFN-beta induction was clearly induced by treatment with EBER+ immunoprecipitates, while no induction was seen upon treatment with immunoprecipitates from EBER negative cells. The induction was reduced by TLR3 knockdown. These results indicate that EBER1 can induce TLR3 signaling in complexes with La.<br /></div><p><br /> </p></li><li><div><strong>EBER1 exists in sera from patients with active EBV infections and induces the production of type I IFN and inflammatory cytokines:</strong> The investigators next extracted RNA from sera or plasma of patients with infectious mononucleosis (IM), chronic active EBV infection (CAEBV), EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) and EBV positive and negative healthy donors and subjected to RT PCR for detection of EBER1. Results showed that EBER1 was detected in patient sera and in sera of healthy individuals. The level of EBER1 was much higher in patient sera than in sera of healthy individuals. No EBER1 was detected in sera of EBV negative healthy individuals. Furthermore, LCLs were treated with this RNA, incubated for 14hrs and subjected to RT PCR to detect IFN-beta and ELISA of the culture supernatant. The results showed that RNAs from those patient sera that contained a high amount of EBER1, induced the release of IFN-beta when added to the culture medium of LCLs. To confirm that IFN-beta production by patient sera was mediated through TLR3, the authors treated LCLs with anti-TLR3 anitbody before subjecting them to RNA from sera of patient. A marked reduction in the RNA-induced release of IFN-beta was observed. These results clearly indicated that RNA from serum induced the expression of IFN-beta through TLR3. The authors also tend to determine whether RNA from patients sera can cause induction of proinflammatory cytokines. Thus, they treated human PBMCs with RNA extracted from patients sera or in vitro synthesized EBER1 and cultured for 14hrs. Induction of IFN-gamma, and TNF-alpha was observed by RNA extracted from patient sera as well as by in vitro EBER1.<br /></div><p><br /> </p></li><li><strong>EBER1 induces mature surface phenotype and antigen presenting capacity of DCs:</strong> To study the effect of EBER1 on DC phenotype, the investigators treated immature DCs with either poly(I:C) or EBER1 for 24 hrs and analyzed the surface markers of matured DCs by flow cytometry. They found that both the treatments caused increased levels of CD83 and CD86, indicating that EBER1 induces maturation of DCs. The treatment with si-TLR3 caused reduction in the up-regulation of CD86, indicating that EBER1 mediated DC maturation is TLR dependent. Next, the authors treated DCs with EBER1 and analyzed the production of IFN-beta and IL-12p40. The results indicated that IFN-beta and IL-12 production by DC was induced by EBER1 and thus EBER causes activation of DCs. To assess whether this activation of DCs by EBER is dependent on TLR3 or not, DCs were transfected with negative control siRNA or siRNA-TLR3 and then stimulated with sera from patients CAEBV containing high amounts of EBER1, low amounts of EBER1 and EBV-negative patients and IL-12 production was determined. The results indicated that the IL-12 production by DCs occurs through EBER1 mediated TLR3 signaling. To further determine whether DCs matured by EBER1 have the capacity for antigen presentation, the DCs treated with EBER1 or poly(I:C) were used for alloMLR assay. Here the authors compared the stimulatory properties of EBER1 or poly (I:C) treated DCs with those of untreated DCs. In this assay, after 24hr stimulation with EBER1 or poly(I:C), DCs were treated with mitomycin. Allo PBMCs were isolated from blood of healthy donors and cultured with mitomycin treated DCs. The PBMC proliferation was then measured using CellTiter 96 nonradioactive cell proliferation assay kit. The results indicated that EBER1-treated DCs were potent inducers of primary allo T cell responses.</li></ul></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com6tag:blogger.com,1999:blog-1418032058537849255.post-24050755645250609792010-11-26T00:13:00.001-08:002010-11-26T00:14:38.048-08:00CD1a-autoreactive T cells are a normal component of the human alpha-beta T cell repertoire<span xmlns=''><p><pre><code><span style='font-family:Calibri'>Source: de Jong A, Peña-Cruz V, Cheng TY, Clark RA, Van Rhijn I, Moody DB. CD1a-autoreactive T <br /></span></code></pre></p><p><pre><code><span style='font-family:Calibri'>cells are a normal component of the human αβ T cell repertoire. Nat Immunol. 2010 Dec;11(12)<br /></span></code></pre></p><p><pre><code><span style='font-family:Calibri'>:1102-9. Epub 2010 Oct 31. PubMed PMID:21037579.<br /></span></code></pre></p><p><br /> </p><p>Members of CD1 system (CD1a, CD1b, CD1c and CD1d) bind and present lipid antigens from mammalian cells and bacteria. Based on results of several experimental studies, it is though that CD1 system is a system which allows T cells to survey CD1-expressing antigen presenting cells for changes in lipid content caused by infection, inflammation or malignancy. Studies suggest that human CD1a, CD1b and CD1c proteins and their non-human orthologs play important roles in immune response. Nearly all mammalian genomes have one or more genes encoding CD1a, and no mammalian species is known to have survived without genes encoding CD1 proteins. This retention of large gene families encoding CD1 proteins in most mammals suggests that each type of CD1 protein has a non-redundant and physiologically important role. Molecular and cellular evidences show that CD1a, CD1b, CD1c and CD1d differ in their transcriptional regulation, patterns of tissue expression, sub-cellular trafficking and antigen grove size. However, it is not known whether these differences also translate in to functional differences in the responding T cell population.<br /></p><p>Human CD1-autoreactive T cells were discovered nearly two decades ago. Most of the insight into function of these cells has been obtained by several T cell clones rather than direct measurement of polyclonal T cells from blood and tissue. These studies have helped in assigning certain unchanging aspects of T cell phenotype such as TCR structure, expression of CD4 and CD8 co-receptors, antigens recognized and molecular mechanism of activation. However, long term culture of human T cells promotes growth of clones with in vitro growth advantage, which is not representative of in vivo repertoires. Even the best available reagents are limited in their ability to track fresh polyclonal T cells, especially CD1-autoreactive T cells. CD1-restricted T cells are able to recognize endogenous lipid antigens. The extent to which a lipid self antigen can be used to track larger pool of autoreactive T cells is unknown. <br /></p><p>The authors sought to overcome these problems by designing a system in which cells provide a diverse pool of lipid antigens for loading onto CD1. The authors further wanted to minimize or remove the normally strong alloreactive responses to MHC class I and class II proteins that would confound with CD1-reactive responses. The authors thus transfected plasmids encoding human CD1 molecules into human myelogenous leukemia cells (K562 cells) that have low to absent expression of MHC. This resulted in MHCs that can be universally used with MHC-mismatched subjects. As these cells express a wide array of self lipid antigens, CD1 autoreacitivity can be detected broadly without prior knowledge of antigen structures. The authors observed that this method detected stronger and more frequent responses to CD1a than to any other human CD1 molecule. The authors also found that CD1a reactive T cells were fundamentally different from CD1d-reactive invariant NKT cells on the basis of their TCR patterns and effector functions. Another important observation that the authors made was that CD1a-autoreactive T cells expressed skin-homing markers and could be isolated from the skin and activated by epithelial CD1a-expressing Langerhans cells (LC). This study identified CD1a-autoreactive cells as subset of human T cells repertoire and defined CD1a as a target of the cells of Th22 helper T cell subset, which suggests a new model of LC-T cells interaction in epithelial homeostasis. <br /></p><p>The results are described in detail below:<br /></p><ul><li><strong>CD1a-autoreactive T cells in peripheral blood:</strong> The investigators first developed a system that can measure the CD1 autoreactivity of non-clonal T cell population ex vivo. They transfected K562 cells, which have low surface density of MHC proteins, with genes encoding CD1a, CD1b, CD1c or CD1d. This resulted in high surface expression of these proteins. The investigators then confirmed the T cell-activating function of each transfected CD1 molecule by the presentation of known exogenous lipid antigens to CD1-restricted control T cell lines. For this experiment, IL-2 was analyzed in supernatant of K562 cells trasnfected with a particular CD1 molecule and incubated with T cell lines recognizing that particular CD1 molecule and exogenous lipid antigen specific for that CD1. For example, they used dideoxymycobactin (DDM) for CD1a, glucose monomycolate (GMM) for CD1b, mannosyl phosphomycoketide (MPM) for CD1c and alpha-galactosylceramide for CD1d. To determine whether CD1-restricted T cells can be detected in human peripheral blood, the investigators analyzed blood samples from 14 donors. Thus, the authors first stimulated polyclonal T cells with DCs expressing CD1a, CD1b, CD1c and CD1d and then analyzed IFN gamma secretion by T cells using CD1-trasnfected K562 cells as APCs. All the 14 donors responded to K562-CD1a cells and the mean responses were greater than those to CD1b, CD1c and CD1d. Three of the 14 donors responded to K562-CD1b, while only one of the 14 donors responded to CD1c or CD1d. Furthermore, the authors took five donors and expanded T cells in the presence of DCs and then tested the restriction of resulting short term T cell lines with K562-CD1a cells in the presence or absence of a CD1a blocking monoclonal antibody. They looked for IL-2 response in these cells. The results showed that a good response was observed when no antibody was present, however when blocking antibody was present , expression of Il-2 was reduced to background level. These results indicated that CD1a on the APCs was required for T cell response. The investigators then took a separate group of 14 donors, stimulated them with autologous DCs and analyzed clonal precursor frequency ex vivo. They generated a panel of 1291 T cell clones and the determined what percentage of autoreactive T cell clones secreted IL-2 in response to K562-CD1a cells relative to mock transfectants. They observed that one in every 50 T cell clones was CD1a autoreactive in 12 out of 14 samples. They analyzed co-receptor expression in 12 samples and found 11 CD4+ single positive clones, 1 CD8+ single positive clone, and no CD4- or CD8- clones. They next sequenced TCR alpha- and beta- chains and found that none of the CD1a-reactive clones expressed the invariant Valpha24 (TRAV10) or Vbeta11 (TRBV25), which are found on human NKT cells. The authors also observed that none of the clones expressed identical CDR3 sequences. Thus, they concluded that CD1a-autoreactive T cells are common in peripheral blood of humans and do not have the highly conserved TCR sequences seen in invariant NKT cells. The authors took eight random donors and purified CD45RO+ memory T cells, treated them with K562-CD1a cells and detected IFN-gamma response using ELISPOT assay. All the eight donors showed IFN-gamma response. Antibody blocking experiments showed that CD1a was necessary and sufficient for the response. The authors estimated the frequency of CD1a-autoreactive T cells to be between 0.02% and 0.4%. As not all CD1a-reactive T cells produce IFN-gamma, the authors performed ex vivo analysis of expanded cell population and found that T cell response to CD1a were of greater magnitude than those to other isoforms of CD1. Taken together these results indicate that CD1a-autoreactive T cells are abundant in blood without immune stimulation and were present in most or all donors. Thus, these cells can be considered to constitute a subset of the normal human alpha beta T cell repertoire. <br /></li><li><strong>Homing of CD1a-autoreactive T cells to skin:</strong> In the periphery, CD1a is found predominantly in skin. Thus, the investigators hypothesize that CD1a-autoreactive T cells in the peripheral circulation might normally home to and localize in the skin. The investigators first determined whether CD1a-autoreactive T cells recovered from the blood expressed skin-homing markers. As it is known that surface expression of homing markers can be rapidly altered during in vitro culture, the authors sorted peripheral blood T cells ex vivo immediately after isolation on the basis of the expression of the membrane marker CD45RO and cutaneous lymphocyte antigen (CLA). The authors earlier made a chance finding of which they took advantage in these experiments. Donor 8 had an autoreactive T cell clone that was isolated from each of the three samples taken for the study. This indicated that these T cells had undergone clonal expansion in vivo. The authors confirmed the clonality of each isolate by expression of identical TCR alpha and TCR beta chains. They were than able to measure the presence of this CD1a specific clone in the naïve T cell fraction, memory T cell fraction and skin-homing memory T cell fraction of the peripheral blood. They found the PCR products for clonotypic primers almost exclusively in the memory T cell fraction (CD45RO+ CLA+). These results indicated that in donor 8, CD1a-autoreactive T cells were CLA+ memory T cells and that CD1a-autoreactive T cells can be a part of skin-homing T cell subset. <br /></li><li><strong>CD1a-dependent IL-22 production: </strong>The investigators next stimulated CD1a-reactive T cell lines with K562-CD1a cells and measured cytokine mRNA by real time PCR. These cytokines included IFN-gamma, IL-2, those associated with T helper 1, T helper 2 and IL-17 producing subsets of MHC-restricted repertoire as well as cytokines produced by CD1d restricted NKT cells. The investigators compared the mRNA produced in response to K562-CD1a cells treated with control IgG with the mRNA produced in response to K562-CD1a cells treated with the CD1a-blocking mAb. Of the eight donors studies in this work, two showed an up-regulation of IFN-gamma alone while five showed an up-regulation of IL-22. The authors also detected secretion of IL-22 protein a dose dependent manner in response to CD1a. The authors observed a lack of substantial CD1a-dependent up-regulation of IL-17 mRNA in most donors and thus they considered that IL-22 and IL-17 are not coordinately upregulated in human CD1a-autoreactive T cells. The authors next performed intracellular cytokine staining of IL-17 and IL-22 in T cell lines from donors showing IL-22 upregulation. The experiments were performed without any stimulation and with stimulation with PMA and ionomycin. The results showed that even in the presence of stimulators, IL-17 production is not induced in IL-22 producing T cell lines. When the authors repeated same experiments in T cell fraction of total PBMCs, the presence of stimulus led to induction of production of both cytokines. These data support the idea that IL-17 and IL-22 represent the effector molecules produced by distinct T cell population in humans. These results also indicate that CD-1a-autoreactive T cells are the ones that produce IL-22. Thus, till now the authors found that a subset of CD1a-autoreactive T cell clones, selected on the basis of their production of IFN-gamma and confirmed for clonality by Vbeta PCR analysis, expressed either IFN-gamma alone or both IFN-gamma and IL-22 in various ratios in response to CD1a. These data provided direct evidence of dual cytokine-producing CD1a-autoreactive T cells at the clonal level and suggested that CD1a-dependent IFN-gamma responses observed by the authors in their previous study were probably both Th1 and Th22-Th1 cells.<br /></li><li><strong>Skin-homing Th22 cells recognize CD1a:</strong> In addition to producing IL-22, Th22 cells are also characterized by expression of the aryl hydrocarbon receptor and expression of the chemokine receptors CCR6, CCR4 and CCR10, which promote skin homing. The authors observed that CD1a-autoreactive T cell lines expressed the aryl hydrocarbon receptor. The authors next sorted memory CD4+ T cells into the following fractions: CCR6+CXCR3+CCR4-CCR10-, CCR6+CXCR3-CCR4+CCR10- and CCR6+CXCR3-CCR4+CCR10+ and measured cytokine profiles in these fractions by RT-PCR. The results confirmed that these three populations were enriched in Th1, Th17 and Th22 cells, respectively. The authors then performed single in vitro expansion of sorted Th1 or Th22 T cell fractions with DCs and cultured them with K562-CD1a cells preincubated with mAb to CD1a or control IgG and observed that in vitro expansion caused twofold or greater CD1a-dependent up-regulation of cytokine mRNA in five of six donor. They also observed that Th22 cells showed the greatest and most frequent CD1a responses. IL-2 and IL-22 were the most dominantly upregulated cytokines in these cells. These results indicate that Cd1a-autoreactive T cells are found in human h22 subset and thus CD1a is a target for Th22 cells.<br /></li><li><strong>CD1a-autoreactive responses from skin:</strong> To assess whether CD1a-autoreactive T cells are present in the skin, the investigators isolated T cells from human skin biopsy specimens and assessed CD1a recognition. During the initial screen, skin T cell clones were isolated whose activation was blocked by mAB to CD1a. The authors next assessed CD1a-dependent production of IL-22 in polyclonal T cells. In case of two samples (out of 3), lymphocytes isolated from human skin showed substantial production of IL-22 in response to K562-CD1a cells but not to K562-CD1b or K562-CD1c cells. These results indicated the dominance of CD1a-mediated responses in healthy human skin and their ability to produce IL-22.<br /></li></ul><p><br /> </p></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-72241536943454988152010-11-22T00:14:00.001-08:002010-11-22T00:14:16.510-08:00Innate and Adaptive T cell Immunity to Campylobacter jejuni<span xmlns=''><p><span style='font-size:10pt'><strong>Source: <br /></strong></span></p><p><span style='font-size:10pt'>Edwards LA, Nistala K, Mills DC, Stephenson HN, Zilbauer M, Wren BW, Dorrell<br /></span></p><p><span style='font-size:10pt'>N, Lindley KJ, Wedderburn LR, Bajaj-Elliott M. Delineation of the Innate and<br /></span></p><p><span style='font-size:10pt'>Adaptive T-Cell Immune Outcome in the Human Host in Response to Campylobacter<br /></span></p><p><span style='font-size:10pt'>jejuni Infection. PLoS One. 2010 Nov 9;5(11):e15398. PubMed PMID: 21085698.<br /></span></p><p><br /> </p><p><em>Campylobacter jejuni</em> is one of the most common causes of gastroenteritis in the world. Infection with this bacteria results in clinical symptoms that can range from mild diarrhea to severe inflammatory enteritis. It has also been linked to subsequent development of Guillain-Barre syndrome (GBS). Due to significant morbidity caused by it in children in the developing world and due to emergence of antibiotic resistant clinical isolates, there is a need to further understand <em>C</em>.<em> jejuni</em> mediated pathogenesis.<br /></p><p>There are some obstacles associated with the study of pathogenesis of and immunity to this pathogen. These are a) no convenient animal model of infection is available, b) it is unethical to perform human studies due to risk of volunteers developing GBS, c) <em>C</em>.<em> jejuni</em> mediated gastritis is self limited d) there is added risk of intestinal perforation due to which it is difficult to investigate immunity to infection in situ.<br /></p><p>The present study is conducted by investigators at Institute of Child Health, London School of Hygiene and Tropical Medicine and Addenbrooke's hospital, Cambridge. In this study, the authors used an ex vivo model of infection which is based on human pediatric small intestine and colonic pinch biopsies in the co-culture system and looked for cytokine production in response to <em>C</em>.<em> jejuni</em> infection. This in vitro organ culture system (IVOC) has earlier been used to study enteropathogenic <em>E</em>. <em>coli</em> infection.<br /></p><p>Previous studies have shown <em>C</em>. <em>jejuni</em> mediated effects on murine and human DC. However, the effect of this interaction of bacteria and DC on human T cells is not known. Thus, the second objective of this work was to look at the impact of bacterial-driven dendritic cell activation on T –cell mediated immunity.<br /></p><p><strong>Results:<br /></strong></p><ol style='margin-left: 38pt'><li><strong>Ex-vivo colonization of human intestine by <em>C</em>. <em>jejuni</em>:</strong> The investigators first sought to determine whether <em>C</em>. <em>jejuni</em> was able to colonize human gut explants tissue in the IVOC model of infection. Thus, they co-cultured human intestinal biopsies from the terminal ileum with wild type (WT) <em>C</em>. <em>jejuni</em> 11168H. Following this, bacteria were localized by immuno-labeling with primary un-labeled anti-Campylobacter antibody and secondary FITC-conjugated antibody. Confocal microscopy revealed that <em>C</em>. <em>jejuni</em> was routinely found in close association with the epithelial lining.<br /></li><li><strong>Ex-vivo release of mucosal cytokines in response to <em>C</em>. <em>jejuni</em> infection:</strong> Pediatric terminal ileum and colonic biopsy tissue were exposed to WT <em>C</em>.<em> jejuni</em> and post-infection production of cytokines was determined. The majority of cytokines were undetectable or minimally expressed in uninfected tissue. Post infection, IFN-gamma showed the most significant induction in both the tissues. IL-22 was secreted spontaneously by both tissues. IL-17 induction was modest. Among cytokines known to influence T cells, IL-23 showed the most significant increase. In contrast, increase in IL-12 and IL-6 was intermediate. <br /></li><li><strong><em>C</em>. <em>jejuni</em> wild type strain drive an IL-23/Il-12 response in monocyte-derived dendritic cells:</strong> The authors next sought to determine the effect of <em>C</em>.<em> jejuni</em> infection on DC cytokine responses. They particular focused on IL-12 family members as they are critical mediators in defining the molecular nature of downstream T cell immunity. The IL-12 family members (IL-12, IL-23, IL-27 and IL-35) are known to share subunits. IL-12 is composed of p35 and p40, IL-23 is composed of p40 and p19, IL-27 is composed of p28 and Epstein Barr virus induced gene 3 (EBI3). The investigators exposed DCs to WT <em>C</em>. <em>jejuni</em> and investigated the expression of IL-12 family subunits by real time PCR. They observed that majority of individuals showed expression of p19, p35, p40 and EBI3 subunits in response to infection, but none of them showed induction of p28. The authors further quantified the cytokine response by ELISA and observed that IL-12, IL-23, IL-1beta and IL-6 were undetectable in DCs exposed to medium alone. In contrast, all four cytokines were induced in the presence of WT <em>C</em>. <em>jejuni</em>.<br /></li><li><strong><em>C</em>. <em>jejuni</em>-infected DCs generate a cytokine milieu that favors single Th-17, Th-1 and double Th-17/Th-1 positive T cell responses:</strong> The authors further tested the ability of supernatants from infected DCs to propagate CD4+CD45RO+ T cell effector responses. They enriched the PBMCs for CD4+CD45RO+ memory T cells and stimulated with anti-CD3, anti-CD28 coated beads for 5 days in the presence of supernatants taken from DCs cultured with medium alone or with WT <em>C. jejuni</em>. They performed flow cytometric analysis and found an increase in single positive IL-17A and IFN-gamma producing T cells and a preferential increase in IL-17A/IFN-gamma double positive T cells. The authors also confirmed the increase in IFN-gamma and IL-17 protein levels by ELISA. <br /></li><li><strong>T-cell derived IL-22 expression in response to <em>C. jejuni</em> infection:</strong> The main source of IL-22 is innate immune cells. However, its expression has also been known to be associated with Th-1, Th-17 and a distinct Th-22-cell subtype. The authors therefore investigated whether <em>C</em>. <em>jejuni</em> infection results in T cells producing IL-22. They performed same experiments as mentioned above and observed that T cell mediated IL-22 expression was indeed observed in the presence of infected DC supernatants. <br /></li><li><strong>IL-17A and F modulate number of intracellular <em>C</em>. <em>jejuni</em> in intestinal epithelia:</strong> Based on the results, the authors hypothesized that in addition to well-established bactericidal and tissue repair functions of IFN-gamma, IL-22 and IL-17, these cytokines may also modulate adhesion and invasion of intestinal epithelial cells (IEC) by <em>C</em>. <em>jejuni</em>. To test this hypothesis, they incubated polarized Caco-2 cells with IFN-gamma, IL-17A, IL-17F or IL-22 for 24 hours and then infected the cells with <em>C</em>. <em>jejuni</em>. At three hours post infection, the investigators performed a standard bacterial adhesion and invasion assay. None of the cytokines were able to modify the number of <em>C. jejuni</em> bacterial cells that adhered to IEC. IL-17A and in particular IL-17F caused reduction in number of viable intracellular bacteria. In contrast, IFN-gamma or IL-22 had no effect on number of viable intracellular bacteria. </li></ol></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com2tag:blogger.com,1999:blog-1418032058537849255.post-69974121497199551702010-11-21T09:35:00.001-08:002010-11-21T09:35:54.422-08:00TLR agonist and Epstein Barr Virus<span xmlns=''><p><pre><code>Source: Iskra S, Kalla M, Delecluse HJ, Hammerschmidt W, Moosmann A. Toll-like<br /></code></pre></p><p><span style='font-family:Courier New; font-size:10pt'>receptor agonists synergistically increase proliferation and activation of B<br /></span></p><p><span style='font-family:Courier New; font-size:10pt'>cells by epstein-barr virus. J Virol. 2010 Apr;84(7):3612-23. Epub 2010 Jan 20.<br /></span></p><p><span style='font-family:Courier New; font-size:10pt'>PubMed PMID: 20089650; PubMed Central PMCID: PMC2838115.<br /></span></p><p><br /> </p><p>EBV maintains itself in its host in latent state for prolonged times. The most preferred host cell type for EBV is B cell. Four modes of latent infection have been described. Mode 0, I, and II are characterized by resting B cell phenotype and expression of very few of EBV proteins. In contrast, mode III involves expression of 12 EBV proteins. The combined action of these proteins induces B cell activation and proliferation, alter receptor expression and enhance antigen presentation.<br /></p><p>Three categories of exogenous physiological signals that lead to B cell activation have been recognized. These are signal 1, the stimulation of B cell receptor by antigen binding, signal 2, stimulation of CD40 by CD40L and signal 3, the stimulation of pattern recognition receptors, TLRs, by microbe associated molecular patterns (MAMP). It is known that combination of all three signals is required for maximal proliferation of naïve B cells. Studies have also reported that stimulation with TLR ligands alone causes transient activation of B cells.<br /></p><p>Earlier studies have established that EBV's latent membrane proteins LMP2A and LMP1 mimic signaling by the BCR and CD40, respectively. However, in case of primary B cell infection by EBV, whether and how a potential signal 3 is generated is not known. Studies have reported that EBV infection of naïve B cells elevates expression of TLR7, thus, TLR7 pathway might play a role in generation of signal 3. <br /></p><p>It is also known from previous studies that other microbial agents present at the site of EBV infection might influence EBV infection, B cell transformation and release of virus. Thus, in the present study, the authors investigate the effects of CpG DNA and other exogenous TLR ligands on EBV driven B cell proliferation, clonal outgrowth and induction of EBV associated cellular receptors and cytokines.<br /></p><p><strong>RESULTS:<br /></strong></p><ul><li><strong>Controlled analysis of infection and transformation by EBV:</strong> EBV particles or their components might trigger TLR mediated activation of B cells. Thus, it was necessary to control for such effects by using virus like particles alongside transformation competent EBV. The investigators used a recombinant EBV system that expresses enhanced GFP. To produce transforming, GFP-encoding EBV, EBV lyric cycle was induced in human epithelial 293 cells that stably carry genomes of this recombinant EBV as episomes. Cells which carry a mutant version of EBV genome (lacking terminal repeats, 293/TR- cells), release virus like particle with empty capsids without DNA. These virus like particles are able to bind to B cells and are also taken up by B cells. When B cells are infected with EBV/TR- (pseudoinfection) there is sufficient uptake of virus particles including GFP and there is also recognition of B cells by CD4+ T cells specific for EBV-proteins. The authors next analyzed virus-associated GFP expression and de novo GFP expression in cells infected with EBV and EBV/TR-. GFP expression was detected in both set of cells on day 1 of post-infection. In contrast, a high increase in fluorescence was observed in cells infected with EBV and not with EBV/TR- on day 3 post-infection. These results indicate de novo expression of GFP from the viral genome. Later on, this GFP-high subpopulation of cells increased in number and dominated the cultures by day 7. These results are consistent with the EBV-mediated B cell transformation. <br /></li><li><strong>Rapid activation and proliferation of B cells in response to EBV:</strong> When B cells are infected with EBV, their phenotype changes from resting to lymphoblastoid one. This phenotype is characterized by larger cell size, enlarged cytoplasm, expression of activation markers and proliferation. To reassess the timing of this process, the investigators infected primary B cells with EBV or EBV/TR- and analyzed cells' scatter characteristics by flow cytometry. On day 3 after infection with EBV and not with EBV/TR-, a distinct population of lymphoblastoid cells with high forward and side scatter levels emerged and continuously expanded thereafter. The authors also looked for surface expression of co-stimulatory surface molecule CD86 on these B cells and found that there was no expression of CD86 on B cells infected with EBV/TR-. In contrast, in cells infected with EBV, CD86 was detected at day 3, highly expressed at day 7 and remained highly expressed thereafter. <br /></li><li><strong>CpG DNA synergistically enhances B cell transformation by EBV:</strong> The authors next infected primary B cells with EBV or EBV/TR- in the presence or absence of CpG DNA. CpG DNA is bacterial or viral DNA containing unmethylated CpG dinucleotides and it is a ligand to TLR9, and it causes activation and proliferation of B cells. On day 7 after infection, infection with EBV alone caused growth of two lymphoblastoid cell lines from resting B cells. EBV/TR- alone produced no lymphoblastoid cells and presence of CpG DNA along with EBV/TR- led to only week production. When CpG DNA was present along with EBV, several lymphoblastoid cell lines were produced. In addition, the immediate presence of CpG DNA was critical for production of lymphoblastoid cells. To further test whether other immune cells could affect the EBV-CpG synergism, the investigators repeated the same experiments with total PBMCs in the presence or absence of Cyclosporin (inhibits T cell activation). They observed that effect of CpG DNA on EBV-mediated production of lymphoblastoid cells from PBMCs and from B cells were similar. They also observed that cyclosporine had no effect. These results indicated that EBV-CpG synergism was mediated by direct effects of EBV and CpG DNA on B cells. The authors also tested whether lymphoblastoid cells detected after EBV infection in the presence of CpG DNA are transformed permanently or not. Their results showed that presence of CpG DNA at the time of EBV infection led to a long term increase in number of transformed B cell clones. The authors further determine live/dead cell ratios in EBV-CpG DNA treated versus EBV-infected B cell cultures. They observed that addition of CpG DNA together with EBV in early infection led to a six fold higher survival rate on the day when lymphoblastoid cell growth was initiated. Combined together, all these results indicate that the presence of a TLR ligand at the site of EBV infection increases the efficiency of infection and transformation of B cells.<br /></li><li><strong>CpG DNA increases activation of B cells by EBV:</strong> To determine whether CpG modifies the expression of CD80 or CD86 molecules on the surface of B cells, the authors infected peripheral B cells with EBV or EBV/TR- in the presence or absence of CpG DNA and analyzed induction of CD80 by flow cytometry. They observed that CD80 induction was highest and fastest after EBV infection in presence of CpG DNA. The authors further looked for secretion of cytokines (IL-6 and IL-10) in these cells. IL-6 was rapidly induced by combined action of EBV and CpG DNA. In contrast, IL-10 secretion was delayed. However, when blocking antibodies against IL-6 or IL-10 were added, no effect on lymphoblastoid cell outgrowth was observed in the early days of infection. Thus, the authors concluded that enhanced IL-6 or IL-10 release is not a major factor in the rapid CpG-mediated increase of outgrowth in the days after EBV infection.<br /></li><li><strong>Susceptibility of naïve and memory B-cell subsets to EBV transformation in the presence of CpG DNA:</strong> The authors isolated peripheral B cells from blood and separated them into naïve (CD27-) and memory (CD27+) B cells. These cells were then infected with EBV or EBV/TR- in the presence or absence of CpG DNA. The results obtained suggested that the synergistic effect of EBV-CpG is similar on both naïve and memory B cells while CpG alone was effective on memory cells only.<br /></li><li><strong>Effect of CpG DNA on early activation of EBV latency genes:</strong> The authors infected primary B cells with EBV in the presence or absence of CpG DNA and analyzed expression levels of EBNA1, EBNA2 and LMP1 genes of EBV at different time points. The authors could see the induction of these genes on infection with EBV, but presence or absence of CpG DNA had little effect. <br /></li><li><strong>Effect of CpG DNA on the induction of EBV's lytic cycle:</strong> The investigators cultivated lymphoblastoid cell lines in the presence or absence of CpG DNA and determined expression levels of five genes from EBV's immediate, early and late lytic stages by quantitative real-time PCR. They observed that most of these genes were downregulated by CpG DNA except BALF4. When the authors tested supernatants of these cells to determine whether they contain EBV that can infect and transform sensitive B cells, they found that supernatants from CpG DNA treated cells had this ability while those from untreated cells did not have the ability to transform B cells. These results suggested that CpG DNA might favor EBV release by latently infected B cells without up-regulation of lytic genes. <br /></li><li><strong>Effects of various TLR ligands or bacteria on EBV transformation of tonsillar or peripheral B cells:</strong> The authors next used various other TLR liagnds e.g., Pam3CSK4 (TLR-2ligand), imiqiomod (TLR7 ligand), LPS (TLR4 lignad), LTA (TLR2 lignad) and whole fixed <em>Staphylococcus aureus</em> bacteria. The authors infected B cells with EBV in presence of these ligands or CpG DNA at various concentrations and analyzed lymphoblastoid cells growth 7 days after infection. The authors observed that several TLR ligands favored the outgrowth of EBV-infected B cells. Of these, CpG DNA had the strongest effect, followed by <em>S</em>. <em>aureus</em> and TLR2 ligand Pam3CSK4 and LTA. Only high concentrations of imiquimod were effective while LPS had no effect. In the presence of EBV TR-, effects of all TLR ligands were small. Not much difference was observed in tonsillar or peripheral B cells. These results suggest that not only agonists of TLR9 but also those of other TLRs, such as TLR2, support EBV-driven B cell activation and early transformation.<br /></li></ul><p><br /> </p><p> </p></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com4tag:blogger.com,1999:blog-1418032058537849255.post-57879435127819046912010-11-16T05:19:00.001-08:002010-11-16T05:19:55.910-08:00Bystander T cells in human immune responses to dengue antigens<span xmlns=''><p>Bystander activation of T cells refers to activation of T cells specific for an antigen X during an immune response against antigen Y. Such an activation of T cells is independent of TCR signaling and occurs through cytokines by novel activating receptors. It has been reported in models of viral infections such as herpes simplex virus, LCMV and HIV leading to proliferation of memory T cells and subsequent production of cytokines. Studies have also found bystander CD8+ T cell activation in response to intracellular bacteria. Dengue viral infection is the cause of dengue fever and dengue hemorrhagic fever. Previous studies have noted that in response to dengue infection, many pro-inflammatory cytokines are released during acute infection. Thus, bystander T cell activation may possibly occur during dengue infection.<br /></p><p>This study was conducted by the lab of Lertmemongkolchai, The Center for Research and Development of Medical Diagnostic Laboratories, Thailand. The investigators aimed to investigate the activation of bystander T cell activation in healthy children living in endemic areas who might be vulnerable re-infection with dengue virus. Thus, they examined IFN-gamma production, which is the established indicator for bystander T cell activation, after restimulating with inactivated dengue viral antigen in vitro. Furthermore, the authors looked for bystander T cell activity by resistance to cyclosporine S (CsA), as CsA is known to inhibit T cell activation by via the TCR dependent pathway.<br /></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'>Source: Suwannasaen D, Romphruk A, Leelayuwat C, Lertmemongkolchai G. Bystander T<br /></span></code></pre></p><p>cells in human immune responses to dengue antigens. BMC Immunol. 2010 Sep<br /></p><p>20;11:47. PubMed PMID: 20854672; PubMed Central PMCID: PMC2949776.<br /></p><p><br /> </p><p>The major results of the study are as follows:<br /></p><ol><li><strong>Healthy Thai school children could produce IFN-gamma in response to inactivated dengue virus serotype 2 in vitro: </strong>The investigator took blood samples from 55 healthy Thai school children and co-cultured them with control (medium alone), stimulators including Phytohemagglutinin (PHA) and combination of cytonies, IL12 and IL15, or Den2 in the presence or absence of CsA for 48 hrs. Cyclosporin A (CsA) is known to inhibit T cell activation via the TCR –dependent pathway. The culture supernatants were then assayed for IFN-gamma by sandwich ELISA. In the presence of positive control stimulators, a higher production of IFN-gamma was observed in compared to negative controls. In the presence of CsA, the production of IFN-gamma was inhibited. This inhibition was observed in case of stimulation by PHA and not with IL-15, IL-12. These results indicate that CsA sufficiently inhibit IFN-gamma production via the TCR-dependent but not the cytokine dependent pathway. The authors also observed that inhibition by CsA in response to Den2 and PHA treatment was very high in comparison to IL-12, IL-15 treatment indicating that IFN-gamma production by Den2 was mainly through TCR dependent pathway. To validate whether CsA does inhibit all TCR-stimulated IFN-gamma activation, the authors used a MHC class I restricted T cell epitope control of pooled peptides (CEF) of cytomegalovirus, EBV and influenza virus. The authors used five whole blood samples from healthy school children and cultured them with medium control, Den2, PHA, and CEF in the presence of absence of CsA. The results showed that CsA completely inhibited IFN-gamma production in response to CEF-stimulation but it only partially inhibits IFN-gamma production in response to stimulation by Den2. These results showed that CsA could inhibit all IFN-gamma production from TCR-dependent activation.<br /></li><li><strong>Identification of IFN-gamma+ cells that respond to Den2</strong>: Eighteen children who showed high IFN-gamma production were followed up to determine the IFN-gamma producing cells. Thus, the investigators co-cultured whole blood samples with medium and 18 HA units Den2 in the presence or absence of CsA. These cells were then analyzed by flow cytometry. The types of IFN-gamma+ cells were then analyzed by the combination of tri-CD3, FITC-CD8 and PE-CD4 or PE-CD56 and compared in the presence or absence of CsA. The results showed that percentage of IFN-gamma + cells in response to stimulation with Den2 was significantly higher than that in response to control (medium alone). In the presence of CsA, there was a change in IFN-gamma+ cells, which was due to decrease in number of NK cells and increase in number of T cells. The results suggested that dengue virus causes bystander T cell activation in vitro as some CD4+ and CD8+ T cells resisted the effect of CsA. The IFN-gamma + cells consisted of NK cells, CD4+ T cells and CD8+ T cells. The distribution of bystander or CsA-resistant CD4+ ranged from 10-59% and distribution of bystander or CD8+ cells ranged from 7-39%. <br /></li><li><strong>Kinetics of bystander T and NK cell activation</strong>: The authors next sought to describe characteristics of activated bystander T cells. Thus, the authors compared kinetics of IFN-gamma production by bystander T cells with those of NK cells and activated specific T cells. The authors studied blood samples from seven school children after 12h, 24h, 36h stimulation. The IFN-gamma+ cells were detected as early as 12h post stimulation. All the seven samples showed similar kinetics of bystander CD4+, CD8+ and NK cells. After 12h post stimulation, bystander CD4+/CD8+ cells were detected while specific CD4+/CD8+ cells were not detected. In contrast, after 24 h post stimulation the proportion of bystander and specific CD4/CD8 cells were equal. <br /></li><li><strong>IL-12 dependent pathway mediated T cell to produce IFN-gamma-</strong> The authors next treated whole blood samples from healthy donors with anti-cytokine antibodies, anti-IL-12, anti-IL-15 and anti-IL-18 and then treated these samples with heat –inactivated <em>Burkholderia pseudomallei</em>, which is a strong bystander or cytokine-dependent T cell inducer. After 48 h, culture supernatants were analyzed for IFN-gamma by ELISA. The results showed that all these three anti-cytokine antibodies could decrease IFN-gamma production by <em>B</em>. <em>pseudomallei</em>. To further investigate the production of IFN-gamma in response to dengue virus, the authors took eleven blood samples from healthy adult blood donors, treated with anti-cytokine antibodies against IL-12, IL-15 and IL-18 and then tested IFN-gamma production from culture supernatants. Anti-IL12 antibody but not anti-IL15 or anti-IL-18 antibody caused a statistically significant reduction in IFN-gamma production in response to dengue virus stimulation. The results suggest that IFN-gamma is mainly activated via IL-12 dependent pathways. When CsA was added in addition to anti-IL12, IFN-gamma production was completely inhibited. The authors then selected three representative blood samples to characterize the intracellular source of IFN-gamma by flowcytometry. They observed that major IFN-gamma producing cells were NK, CD4+ and CD8+ T cells. The authors next selected two representative samples to determine the effect of neutralizing antibodies on IFN-gamma production. Results showed that anti-IL12 and CsA cause a decrease in IFN-gamma producing cells derived from both CD4 and CD8 cells. The results also showed that CD4+ T cells were equally sensitive to anti-IL-12 and CsA, while CD8+ T cells were less sensitive to anti-IL12 than CsA. These results confirmed that bystander T cells are produced in response to dengue virus and these T cells produce IFN-gamma via IL-12 dependent pathway.<br /></li></ol></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com1tag:blogger.com,1999:blog-1418032058537849255.post-48815436574378804182010-11-11T06:31:00.001-08:002010-11-11T06:31:09.469-08:00Pneumocystis infection enhances antibody-mediated resistance to a subsequent influenza infection<span xmlns=''><p><pre><code>Source: Wiley JA, Harmsen AG. Pneumocystis infection enhances antibody-mediated<br /></code></pre></p><p><span style='font-family:Courier New; font-size:10pt'>resistance to a subsequent influenza infection. J Immunol. 2008 Apr<br /></span></p><p><span style='font-family:Courier New; font-size:10pt'>15;180(8):5613-24. PubMed PMID: 18390746; PubMed Central PMCID: PMC2600725.<br /></span></p><p><br /> </p><p><br /> </p><p>In the lung concurrent immune responses can occur. These occur due to <br /></p><ol><li>Simultaneous and/or consecutive exposure to multiple pathogens or immunogens<br /></li><li>Exposure of asthamatic patients to pulmonary pathogens<br /></li><li>When pathogen associated immune responses interact with responses to underlying chronic pulmonary diseases involving infections or COPD or emphysema<br /></li></ol><p>The progression of concurrent immune responses in the lung can lead to beneficial or detrimental outcomes. In the present paper, the authors tried to further look at this area by using co-infection with two different but regularly encountered pulmonary pathogens that elicit opposing immune responses. They used <em>Pneumocystis murina</em>, which elicits a type 2 immune response and influenza type A virus, which elicits a type 1 immune response. <br /></p><p>The major results of the studies are as follows:<br /></p><ul style='margin-left: 38pt'><li><strong>Pathogen recovery from lungs:</strong> Mice were infected with <em>Pneumocystis</em>-infected lung homogenate and after 2-3 weeks they were infected with influenza. The control mice were given uninfected lung homogenate 2-3 weeks prior to influenza infection. Viral recovery by plaque assay was determined in co-infected mice after 1 week of influenza infection. In another set of experiments the sequence of co-infections was reversed. When Pneumocystis infection was initiated two weeks prior to influenza infection, the recovery of influenza virus decreased 100 fold in comparison to control mice. In contrast, when <em>Pneumocystis</em> infection was initiated three weeks prior to influenza infection, recovery of virus decreased to 10 fold. The authors further examined the rate of clearance of virus in two weeks apart co-infection model and control mice over a 10 day period following virus challenge. The greatest difference in viral clearance among the two groups was observed after seven days. Thus, the results suggested Pneumocystis infection two weeks prior to influenza infection caused reduction in influenza virus recovery. <br /></li><li><strong>Analysis of cell recovery in BALF:</strong> The lungs of each animal were lavaged 1 week after co-infection with the influenza virus. Lymphocytes and macrophages were present in equal numbers among the two groups during the resolution of influenza infection. In contrast, neutrophils were significantly higher in airways of control mice. Among the co-infected models, neutrophils were same as those present at day 0 of influenza infection after <em>Pneumocystis</em> infection. The eosinophils remained at negligible levels in the influenza only control animals. The number of eosinophils was high both at the time of influenza and during resolution in co-infection models. <br /></li><li><strong>Change in weight:</strong> The authors also examined change in weights of both groups of animals following influenza infection. Over the 10 days following the influenza infection, co-infected animals lost least amount of weight. In contrast, influenza only control animals continued to lose weight. <br /></li><li><strong>Recovery of serum albumin and lactate dehydrogenase in BALF:</strong> Levels of albumin and LDH generally increase during lung damage and thus this increase has been used as an indicator of lung damage. In the present study, the authors observed that both albumin and LDH levels remained same at day 0 and day 7 in co-infected animals. In contrast, significant increase in albumin and LDH levels was observed in influenza only control animals. <br /></li><li><strong>Recovery of inflammatory cytokines in BALF:</strong> The levels of inflammatory cytokines, TNFalpha, IL-10, IFN, IFN-gamma, MCP-1 and IL-6 were significantly reduced in co-infected animals compared to control animals. <br /></li><li><strong>Germinal center B cell analysis:</strong> The investigators also performed FACS analysis of GC B cell proliferation on spleen and local tracheal-bronchial lymph node (TBLN). The authors observed that GC B cell proliferation was greater in both spleen and TBLN in co-infected animals and in control mice 1 week after influenza infection. <br /></li><li><strong>Influenza antibody titers detected in the BALF and serum:</strong> In order to determine whether immune response to the Pneumocystis infection altered the local and/or systemic influenza specific antibodies levels, the authors also sought to determine the influenza specific antibodies. They observed that in lungs of co-infected animals, influenza specific IgA, IgG and IgM antibodies appeared earlier and remained at significantly higher levels following influenza infection. <br /></li><li><strong>Absence of antibody negates enhanced viral clearance in co-infected mice:</strong> The authors found out that there is rapid appearance of influenza specific antibodies, which could be responsible for effective viral clearance. Thus, to determine whether the enhanced rate of viral clearance in case of co-infected animals was due to influenza specific antibodies, the authors co-infected uMT (mice generated by disruption of one of the membrane exons of the u-chain gene and have no detectable B cells or circulating antibody but have normal T cells), SCID and immunocompetent mice. They found that virus recovery in uMT co-infected mice and uMT- influenza only mice was same at seven days prior to influenza infection. The levels of viral recovery were equivalent between all of the SCID and uMT infection groups. Among the wild type mice, significant differences in virus recovery were observed among the co-infected mice and influenza only infected mice.</li></ul></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com1tag:blogger.com,1999:blog-1418032058537849255.post-9172030727611004822010-10-16T05:29:00.001-07:002010-10-16T05:29:17.502-07:00NKT cells and SAP<span xmlns=''><p><pre><code><span style='font-family:Calibri; font-size:11pt'><strong>Source: Chung B, Aoukaty A, Dutz J, Terhorst C, Tan R. Signaling lymphocytic<br /></strong></span></code></pre></p><p><strong>activation molecule-associated protein controls NKT cell functions. J Immunol.<br /></strong></p><p><strong>2005 Mar 15;174(6):3153-7. PubMed PMID: 15749842.<br /></strong></p><p><br /> </p><p>X-linked lymphoproliferative disease (XLP) is a primary immunodeficiency disorder, which is caused by mutation in the gene Src homology 2 (SH2) domain containing gene 1A (SH2D1A). This gene encodes signaling lymphocyte activating molecule (SALM)-associated protein (SAP). There are many evidences that indicate that SAP plays a role in regulation of lymphocytes. <br /></p><ul><li>The clinical course of XLP consists of uncontrolled proliferation of B and T cells.<br /></li><li>Studies have observed that SAP knock out (SAPKO) mice generate abnormally large virus specific CD8+ and CD4+ T cell following infection with LCMV. <br /></li><li>It has also been observed that SAP binds to intracellular domains of SLAM and B4, both of these are immuno-regulatory molecules, which are primarily expressed on T cells and NK cells, respectively.<br /></li><li>SAPKO mice are unable to generate memory B cell response.<br /></li></ul><p>Despite all these evidences about role of SAP in controlling lymphocyte proliferation, a role for SAP in NKT cells development and function, a type of regulatory cells, is not known. It has been previously reported that CD1d restricted NKT cells control EBV-specific lymphocyte proliferation [Ho et al., 2004 (CD4-CD8alphaalpha subset of CD1d-restricted NKT cells controls T cell expansion)]. This can be due to a possible link between NKT cell function and large T cell expansions seen in XLP patients following EBV infection. <br /></p><p>In a beautiful paper published in 2005 from the labs of Dr. Rusung Tan, the investigators sought to determine the role of NKT cells in the immune dysregulation of SAPKO mice.<br /></p><p>Their findings are briefly described below:<br /></p><ol><li>SAPKO mice completely lack CD1d restricted NKT cells.<br /></li><li>When SAPKO mice were injected with potent NKT agonist alpha-GalCer, the mice did not develop or activate NKT cells that produce cytokines (IFN-gamma and IL-4).<br /></li><li>When SAPKO mice were co-injected with OVA and alpha-GalCer, the mice did not show OVA specific CTL responses.<br /></li><li>Patients with XLP did not have a population of CD1d restricted NKT cells in their peripheral blood.<br /></li></ol><p>All these findings indicated that SAP is critical for normal CD1d restricted NKT cell development and function.<br /></p><p><br /> </p><p><strong>Performance of experiments:<br /></strong></p><ul><li>SAPKO mice and wild type mice were taken and SAP gene expression was confirmed by PCR and immunoprecipitaion. Lymphocytes were stained with Abs to CD3 and NK1.1, these two molecules are the markers present on murine NKT cells, and flow-cytometric analyses were performed. The investigators observed that frequency of CD3+ NK1.1+ NKT cells from liver, thymus, spleen and lymph nodes was significantly low in SAPKO mice in comparison to wild type. An earlier study (Hammond et al., 2004) has shown that NK1.1 expression may not be the ideal marker for CD1d restricted NKT cells as many of the CD1d restricted cells fail to express NK1.1. Thus, Dr. Tan and his team used CD1d tetramer and Ab to TCRVbeta8 to stain lymphocytes from spleen, liver, thymus and lymph nodes from SAPKO and wild type mice. The data obtained confirmed that <span style='text-decoration:underline'><strong>SAPKO mice lack CD1d-restrcited NKT cells</strong></span>.<br /></li><li>Up on activation NKT cells rapidly produce cytokines. The investigators thus hypothesized that since SAPKO mice lack CD1D-restricted NKT cells, they would not produce these cytokines upon activation. Thus, SAPKO and wild type mice were intra-peritoneally injected with alpha-GalCer and liver cells were isolates after 2 hrs. These cells were stained with CD1d tetramer to identify CD1d-restricted NKT cells and intracellular cytokine staining was performed using anti-IFN-gamma-allophycocyanin or anti-IL4-allophycocyanin. The authors observed no CD1d restricted NKT cells and no IFN-gamma or IL-4 production in SAPKO mice. In contrast, wild type mice produced significant amount of IFN-gamma and IL-4. These findings indicate that <span style='text-decoration:underline'><strong>SAPKO mice are unable to mount a rapid NKT-induced cytokine response</strong></span>.<br /></li><li>A previously conducted study showed that NKT cells not only regulate LCMV-induce cytokine production, but they also controlled the magnitude of the cell-mediated immune response to an acute viral infection. Thus, NKT cells are important for generation and regulation of antigen specific T cells. Thus, to determine whether NKT cells are important for activation or proliferation of antigen specific T cells, the authors immunized SAPKO and wild type mice with vehicle (a control for alpha-GalCer) and OVA, CFA or alpha-GalCer. At day 14, PBMCs were isolated and stained with Kb-OVA254-267 tetramers and CD8 Ab to measure OVA-CTL expansion. Wild type mice showed significant CTL-expansion in comparison to SAPKO mice immunized with OVA and alpha-GalCer. These data indicate that the <span style='text-decoration:underline'><strong>generation of Ag-specific CTL response is promoted by CD1d restricted NKT cells and SAPKO mice are unable to generate CTL in response to immunized Ag and NKT cell agonist</strong></span>.<br /></li><li>The scientists also took peripheral blood from two XLP patients, who had mutations in the second exon of SAP, and stained the PBMCs with CD1d tetramer and anti-CD3 Ab. They followed the same experiments in eight healthy individuals. The healthy controls showed significant percentage of CD1d-restricted NKT cells in comparison to XLP patients, indicating that <span style='text-decoration:underline'><strong>CD1d-restricted NKT cells are absent in XLP patients.</strong></span><br /> </li></ul><p><br /> </p><p><strong>Conclusions:<br /></strong></p><p>NKT cells act as a bridge between innate immune response and adaptive immune response by rapidly activating NK cells and helping in maturation of DCs. Thus, the authors hypothesized that in the absence of NKT cells, the immune response to virus is sub-optimal. Thus, viral replication occurs unchecked leading to formation of a chronic viral stage. It has been observed that boys with XLP disease show continuous viremia with EBV during the course of diseases. Such uncontrolled virus infection may lead to chronic stimulation of virus specific CTLs that are not efficient to clear virus-infected cells. <br /></p></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-58310129411076340562010-10-14T10:25:00.001-07:002010-10-14T10:28:07.336-07:00NKT cells suppress EBV-associated tumors<span xmlns=''><p>EBV, a first discovered human tumor virus, is considered to be one of the most successful human pathogen. It is involved in the development of many malignancies, such as Hodgkin's lymphoma and nasopharyngeal carcinoma in immunocompromised individuals. Majority of the individuals infected with EBV remain symptom free. Thus, it is believed that EBV has co-evolved with the human immune system to a peaceful co-existence.<br /></p><p> It is known that natural killer T cells (NKT) are a special type of T cells that express NK lineage receptors including CD1d. They respond to glycolipid antigen presented by CD1d. CD1d is mainly expressed on antigen presenting cells (APCs, dendritic cells, macrophages and B cells). Thus, NKT cells primarily interact with APCs rather than tissues. Upon activation, these NKT cells release both Th1 and Th2 cytokines. However, it is present not known whether there are subsets of NKT that specialize in Th1 and Th2 cytokine production. Furthermore, how these cytokines lead to a regulated immune response in vivo is not known. Earlier studies have suggested that cytokine profile of NKT cells might be influenced by quality of TCR signal. The quality of TCR signal is in turn dependent on different antigens. <br /></p><p>The present paper is from the lab of Dr. Yuling He, Wuhan University School of Medicine, China. In an earlier paper, the authors observed that CD8+ NKT cells drive syngenic T cells into a Th1-bias response to suppress EBV-associated malignancies and that IL-4-biased CD4+ NKT cells do not affect T cell cytotoxicity. In the present work, the authors sought to determine the mechanism of the EBV-induced CD8+ NKT cell response to EBV-associated malignancies.<br /></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'>Source: Xiao W, Li L, Zhou R, Xiao R, Wang Y, Ji X, Wu M, Wang L, Huang W, <br /></span></code></pre></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'>Zheng X, Tan X, Chen L, Xiong T, Xiong J, Jin Y, Tan J, He Y. EBV-induced <br /></span></code></pre></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'>human CD8(+) NKT cells synergise CD4(+) NKT cells suppressing EBV-associated<br /></span></code></pre></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'>tumours upon induction of Th1-bias. Cell Mol Immunol. 2009 Oct;6(5):367-79.<br /></span></code></pre></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'>PubMed PMID:19887050.<br /></span></code></pre></p><p><strong>RESULTS:<br /></strong></p><ol style='margin-left: 38pt'><li><strong>Circulating mDC1cells from patients with EBV-associated malignancies impaired IFN-gamma production of CD8+ NKT cells:</strong> In another previous study, the authors observed that the frequencies of total and CD8+ NKT cells in PBMCs from Latent EBV infection (LEI) and control negative subjects (CN) were significantly higher than those from Hodgkin lymphoma (HL) patients and nasopharyngeal carcinoma (NPC) patients. To determine the interaction of CD8+NKT cells with APCs, the authors first determined frequencies and CD1d expression of circulating DCs, which included myeloid dendritic cells 1 and 2 (mDC1 and mDC2) and plasmacytoid dendritic cells (pDC), in PBMCs from NC and LEI subjects , and HL and NPC patients by staining with different markers, BDCA1 for mDC1, BDCA2 for pDC and BDCA3 for mDC2 and CD1d. The frequencies of mDC1 cells were comparable among HL and NPC patients, and LEI and NC subjects. CD1d was found to be predominant expressed on mDC1 cells than mDC2 and pDC cells. The expression level of CD1d was comparable on LEI and NPC subjects and HL and NPC patients. The authors next determined cytokine expression by CD4+ and CD8+ NKT cell lines. These cell lines were generated from PBMC from LEI subjects. Type 1 mDCs were purified from LEI and NC subjects and HL and NPC patients. These mDCs were than co-cultured with CD4+ or CD8+ NKT cell lines in the presence of alphaGalCer or alphaGalCer with CD1d mAb for 1 hr. The mDCs were then re-purified using staining with alpha-GalCer loaded CD1d tetramer. Then, the expression of IFN-gamma and IL-4 was assessed by Q-PCR. Both IFN-gamma and IL-4 were detected in CD4+ and CD8+ NKT cell lines cultured with mDCs from different groups of patients and subjects. The authors observed that both NKT cell lines from LEI and CN subjects highly expressed IFN-gamma upon stimulation with alphaGalCer. Although, not much effect was seen on IL-4 expression among various patients and subjects. Furthermore, using the same set of experiments the authors determined IFN-gamma and IL-4 expression by using ELISA. They observed that prestimulation with alphaGalCer caused significant increase in expression level of IFN-gamma in CD8+ NKT cell lines incubated with PBMCs from LEI and CN than from HL and NPC patients. IL-4 levels were in CD4+ NKT cells cultured with PBMCs from both patients and subjects. These results indicate that circulating mDC1 cells of HL and NPC patients cause a decrease in IFN-gamma production by CD8+ NKT cell line and have no effect on IL-4 production.<br /></li><li><strong>EBV induced CD8+ NKT cells promote a Th1 biased response that suppresses EBV-associated tumor cells in vitro:</strong> The authors observed in one of their early study that CD4+ NKT cells in PBMCs from HL and NPC patients and LEI and CN subjects produced similar low levels of IFN-gamma and high levels of IL-4, IL-13, IL-10 and TGF-beta1. In contrast, CD8+ NKT cells from control subjects produced expressed high levels of IFN-gamma and IL-2 but low levels of IL-4, IL-13, IL-10, and TGF-beta1. They also found that CD8+ NKT cells from LEI and CN subjects efficiently killed alpha-GalCer loaded EBV-associated HL and NPC tumor cell lines but not non-tumor cells. CD4+ from various patients and subjects either did not show such killing or showed very weak toxicity to both tumor and non-tumor cells. In the same study, the authors also observed that EBV-induced human NKT cells rapidly responded to EBV-associated tumor cells by secreting cytotoxic cytokines such as IL-10 and IFN-gamma. In the present study, the authors tried to verify whether this killing was specific, the authors first demonstrated present of EBV through the use of southern blot and QPCR in these cell lines. Thus, EBV-genes, LMP1, EBNA1, BZLF1, BALF2, and RAZ were examined in human EBV-associated tumor cell lines and non-tumor cell lines. The authors were able to detect these viral genes and their mRNA transcripts in tumor cell lines but not in non-tumor cell lines. The next task was to determine the mechanism by which NKT cells inhibit EBV-associated malignancies in vivo. Thus, the authors established hu-thym-SCID chimaeras. These chimaeras were implanted with human Hodgkin´s-derived EBV-associated B-cell lymphoma cell lines (LBC) or NPC. The animals were sacrificed 12 weeks post tumor implantation. Various organs including thyms, liver spleen and peripheral blood were collected and single cell suspensions were prepared. These cells were stimulated with alphaGalCer and cytokine expression (IL-4, IL-10 and IFN-gamma) was determined, using cytokine Ab, CD4 Ab, CD8 Ab and CD1d tetramer. The authors observed that a large number of CD8+ NKT cells expressed IFN-gamma and IL-2, but few cells expressed IL-4, IL-10 and IL-13. In contrast, CD4+ NKT cells expressed moderate levels of IL-4, IL-10 and IL-13 and low levels of IFN-gamma. <br /></li><li><strong>EBV- induced CD4+ NKT cells synergized with CD8+ NKT cells to promote a Th1 bias response against EBV-associated tumors:</strong> In their earlier work, the authors observed some kind of synergy between EBV-exposed thymic CD4+ and CD8+ NKT cells to suppress EBV-associated malignancies and prolong animal survival. To further investigate the mechanism of this synergistic effect, the SCID mice were adoptively transferred iv with different combinations of immune cells (CD4+/CD8+ NKT cells or both and CD3+CD56-Cd161- T cells) purified from EBV-exposed hum-thym-SCID chimaeras. After, three days these chimaeras were re-challenged with EBV. The scientists observed that in chimaeras transferred with CD4+ NKT cell alone, the re-challenge with EBV caused inhibition in proliferation of CD3+ T cell in comparison to chimaeras transferred with CD8+ NKT cell alone. Interesting, the chimaeras transferred with both CD4+ and CD8+ NKT cells showed a vigorous proliferation of CD3+ T cells and a high frequency of IFN-gamma producing cells.<br /></li></ol><p><strong>To be continued……………….</strong></p></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-28595055405283326982010-10-12T03:41:00.001-07:002010-10-12T03:52:12.162-07:00ESCRT factors restrict mycobacterial growth<span xmlns=''><p>Mycobacterium tuberculosis is considered as one of the most successful pathogen. Some of the reasons that are responsible for its success include its ability to survive within the macrophages. But how does the bacteria survive intra-cellularly is not known. In the present paper, the authors have tried to address this question.<br /></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'><strong>Source: Philips JA, Porto MC, Wang H, Rubin EJ, Perrimon N. ESCRT factors <br /></strong></span></code></pre></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'><strong>Restrict mycobacterial growth. Proc Natl Acad Sci U S A. 2008 Feb 26;105<br /></strong></span></code></pre></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'><strong>(8):3070-5. Epub 2008 Feb 19. PubMed PMID: 18287038; <br /></strong></span></code></pre></p><p><pre><code><span style='font-family:Calibri; font-size:11pt'><strong>PubMed Central PMCID: PMC2268586</strong></span>.<br /></code></pre></p><p><br /> </p><p>It is known that virulent mycobacterial are able to alter the maturation of phagosome inside the macrophages. They reside in a cellular compartment that resembles an early endosome. This endosome retains early endosome markers such as Rab5 and fails to recruit mature enodosomal markers such as Rab7. <br /></p><p>In an earlier study, the authors performed a functional genomic screening to identify host factors, which can influence the uptake and growth of Mycobacteria. The authors used Drosophilla S2 cells, a macrophage like cell line that is open to RNAi and M. fortuitum, which like M. tuberculosis restricts phagosome fusion with lysosomes. M. fortuitum was able to induce the expression macrophage activated promoters (maps), which are the bacterial genes that are specifically induced when the bacteria grows intra-cellularly. Thus, by visualizing GFP (Green fluorescent proteins, proteins that produce free fluorescence when exposed to blue light) produced under the control of the map24 promoter, the authors were able to monitor the bacterial response to the intracellular environment. In another previous study, the authors identified 86 dsRNAs, which were able to diminish bacterial GFP production. As production of GFP reflects both the bacterial response to the phagosomal environment and bacterial growth, these dsRNAs can affect the infection by altering bacterial uptake, intra-cellular bacterial growth or induction from the map24 promoter. <br /></p><p>In the present study, the authors further characterized three host cell activities Rab7, CG8743, and the ESCRT machinery. First to check the affect of dsRNAs, they used M. smegmatis, as it is difficult to measure intra-cellular growth of M. fortuitum. Thus, they examined two possibilities, if dsRNA treatment results in less intra-cellular growth of M. fortuitum and then it should have little effect on M. stegmatis because they do not grow in S2 cells. The other possibility was if the dsRNA altered phagosome environment and caused diminished map induction, then treatment with dsRNA should cause increase in permissiveness of phagosome for bacterial growth and M. stegmatis should grow. They treated S2 cells with dsRNA and then infected them with M. stegmatis. After two days, cells were examined by microscopy. They observed that four dsRNAs out of 86 strongly increased the percentage of heavily infected cells. These dsRNAs targeted Rab7, dVps28, CG8055 and CG8743. To confirm that bacterial growth was occurring intra-cellularly, they further blocked the bacterial uptake by using a dsRNA which targets Pes, a receptor required for entry of bacteria into the cell. The investigators observed that blocking did not cause any increase in bacterial growth and thus the results indicated that growth must be occurring intra-cellularly. Based on these results, the authors suggested that Rab7, dVps28, CG8055 and CG8743 might be playing important roles in restricting the intracellular growth of M. stegmatis. <br /></p><p>Rab7 is a GTP binding protein and a marker for late enodosome. But the role of dVps28, CG8055 and CG8743 are not known. dVps28 and CG8055 are members of ESCRT machinery, which is made up of three proteins ESCRTI, ESCRTII and ESCRTIII. The authors thus, tested the effect of other dsRNAs that target additional ESCRT components on M. stegmatis growth. The authors observed that all dsRNAs, which robustly disrupt ESCRT machinery, caused increased growth of M. stegmatis and also altered the phagosome environment resulting in map24 and map49 induction by M. fortuitum and increased growth of M. stegmatis.<br /></p><p>It is known that the ESCRT machinery acts on the membrane of the endosome. its function is to deliver ubiquitinated receptors into intraluminal vesicles of multivesicular bodies. These bodies are finally delivered to the lysosome for degradation. In Drosophila, a lack of ESCRT functioning causes accumulation of enlarged endosomes with accumulation of ubiquitin.<br /></p><p>The authors next sought to determine whether ESCRT machinery acts directly on mycobacterial phagosome. They examined the localization of bacteria in ESCRT-depleted cells. S2 cells, which were depleted of dTsg101 and Vps28 (part of ESCRTI) were infected with M. stegmatis. After three hrs of infection, bacteria were found within the heavily ubiquinated vesicular compartments. These results showed that bacteria reside in the compartment on which ESCRT machinery acts. These results indicate that ESCRT machinery directly acts on the bacterial phagosome.<br /></p><p>To test whether ESCRT machinery affects mycobacterial growth infection in mammalian macrophages, the authors depleted dTsg101 and Vps28 from murine macrophages RAW264.7 using SiRNA. These cells were then infected with M. fortuitum map24:GFP. The depletion caused less GFP production when cells were infected with M. fortuitum map24:GFP in comparison to controls. To further determine whether phagosome in ESCRT depleted cells was also less restrictive for mycobacterial growth, Raw264.7 cells were depleted of dTsg101 and Vps28 and infected with M. smegmatis hsp60::GFP. In control cells there was little growth 24 hrs post infection. In contrast, substantial growth was observed in depleted cells. Thus, the authors concluded that ESCRT machinery is required to restrict the growth of M. stegmatis in mammalian macrophages.<br /></p><p>The diminished GFP production in cells depleted of ESCRT and infected with M. fortuitum map24:GFP is due to diminished expression and not due to decreased bacterial growth. To validate this, the authors used an M. fortuitum strain that expresses both red fluorescent protein (dsRed2) and GFP under control of two separate promoters. dsRed2 is under the control of msp12 promoter and is constitutively expressed. GFP is expressed under the control of map49, which is induced during intracellular growth. When ESCRTI depleted cells were infected with this bacteria, the authors observed diminished GFP expression as early as 3 hrs post infection. Examination of red fluorescence however, revealed that bacterial uptake was similar in both depleted and control cells and bacterial growth was similar or slightly increased in controls. These results suggested the phagosomal environment in ESCRT depleted cells was different from the non-depleted cells. The effect of this difference is such that the induction from the map24 and map49 promoters was decreased and bacterial growth is not efficiently restricted. <br /></p></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com13tag:blogger.com,1999:blog-1418032058537849255.post-21841055950030082852010-10-11T00:21:00.001-07:002010-10-11T00:23:35.252-07:00Evaluation of a novel Mycobacterium tuberculosis protein in the immunodiagnosis of TB<span xmlns=''><p><pre><code><span style='color:#943634'><strong>Source: Singh KK, Sharma N, Vargas D, Liu Z, Belisle JT, Potharaju V,<br /></strong></span></code></pre></p><p><pre><code><span style='color:#943634'><strong> Wanchu A, Behera D, Laal S. Peptides of a novel Mycobacterium tuberculosis<br /></strong></span></code></pre></p><p><pre><code><span style='color:#943634'><strong>-specific cell wall protein for immunodiagnosis of tuberculosis. J Infect Dis.<br /></strong></span></code></pre></p><p><pre><code><span style='color:#943634'><strong>2009 Aug15;200(4):571-81<br /></strong></span></code></pre></p><p><br /> </p><p><em>Mycobacterium tuberculosis</em> is an opportunistic pathogen that causes nearly 2-3 million deaths each year. One of the common methods of diagnosis is by microscopic identification of acid fast bacilli in sputum samples. However, the procedure is tedious, and requires multiple samples. Also, the success rate of correct diagnosis has been reported to be 30-60%. Thus, rapid, point-of-care diagnostic tests are required. Currently, there is no sero-diagnostic test that provides accurate diagnosis of <em>M</em>. <em>tuberculosis</em> infection. Many studies are going on to discover and identify new proteins of this pathogen, which can then be used to develop sero-diagnostic tests.<br /></p><p>The authors of this paper previously identified a proline-threonine repetitive protein (PTRP; Rv0538) in aerosol infected rabbits. Earlier studies have shown that it is present in the cell wall. The authors of this paper also observed in their previous study that this protein does not have a homolog in <em>M</em>. <em>avium</em> and <em>M</em>. <em>leprae</em>.<br /></p><p>Thus, the previous findings of immunogenicity of PRTP in rabbits, cell wall localization of this protein and its absence in the <em>M. avium</em> and <em>M. leprae</em>, made the authors to further characterize this protein and study its diagnostic potential.<br /></p><p>The results obtained are discussed below:<br /></p><ol><li><strong><em>ptrp</em> is specific for <em>M. tuberculosis</em> (complex):</strong> The authors performed a protein BLAST analysis of PTRP. The results showed nearly 100% identity with a protein in <em>M. tuberculosis</em> CDC1551, <em>M. tuberculosis</em> F11, <em>M. tuberculosis</em> C, <em>M. tuberculosis</em> H37Ra, <em>M. bovis</em> AF2122/97 and <em>M. bovis</em> BCG strain. No such identity was observed in pathogenic non-tuberculous mycobacterial species. Nucleotide BLAST analysis of <em>ptrp</em> gene identified nearly 100% identical genes in <em>Mycobacterium tuberculosis</em> complex species and clinical isolates but not in the non-tuberculous mycobacterial species. The specificity of <em>ptrp</em> to the <em>M. tuberculosis</em> complex was further confirmed by Southern hybridization.<br /></li><li><br /> <strong>Expression and purification of rPTRP: </strong>The PTRP protein was expressed and purified and its molecular weight was nearly 52kDa. Its identity was confirmed by sequencing.<br /></li><li><strong>PTRP is a cell wall protein of <em>M. tuberculosis</em>:</strong> To confirm the localization of this protein, sub-cellular protein fractions of <em>M. tuberculosis</em> were separated on a Western Blot and probed with pre-immune IgG, anti-PTRP IgG and anti-MS (malate synthase) IgG antibodies. Anti-PTRP antibodies identified a nearly 52KDa protein in total cell wall (TCW), SDS extracted cell wall (SDS-CW) of <em>M. tuberculosis</em>. Some weak reactivity was also observed in whole cell lysate (WCL), but no similar protein was observed in culture filtrates. It has been shown through earlier studies that malate synthase (MS) of <em>M. tuberculosis</em> is anchored to the cell wall. Thus, to estimate the relative abundance of PTRP in different cell preparations, the authors used anti-malate synthase (MS) IgG. With quantity of MS in each fraction considered to be 100%, WCLs were found to contain less PTRP than the TCW and SDS-CW. Finally, the presence of PTRP on cell wall was confirmed by immuno-electron microscopy. <br /></li><li><strong>Immunogenicity of PTRP in patients with TB:</strong> To determine the immunogenicity of PTRP in patients with TB, the reactivity of rPTRP was examined with serum specimens from patients with TB and healthy controls. The investigators observed that serum antibodies from 4 of the 6 HIV-negative TB positive and 5 of 6 HIV positive and TB positive patients displayed strong reactivity with rPTRP. None of the 6 HIV negative PPD positive, 6 HIV negative PPD negative or 6 HIV positive, TB negative patients showed any reactivity with rPDRP.<br /></li><li><strong>Identification of immunogenic epitopes of PTRP:</strong> The authors next checked the diagnostic potential of PTRP. Thus, they synthesized fifty-four overlapping peptides (20 aa in length with a 10-aa overlap; PT1–PT54) covering the entire PTRP sequence, each linked with a biotin residue at the N-terminal. Out of these 54, 53 peptides were tested for their reactivity with serum specimens from 13 PPD-negative and 23 PPD-positive healthy control subjects. No significant difference was observed in the reactivity of 49 peptides. No control serum tested positive with 22 of 53 peptides. The remaining peptides were recognized by the antibodies in only one or two serum specimens. When the 53 peptides were tested for their reactivity with serum specimens from HIV negative, TB positive patients, 16 of 53 peptides were recognized by antibodies from more than 40% of the patients with TB. Of these 16 peptides, 12 were reproducibly recognized by antibodies in specimens from more than 40% of patients with TB. Out of these 12 peptides, 4 were recognized by antibodies from specimens from more than 50% of patients with TB. These are PT9, PT13, PT40 and PT41.<br /></li><li><strong>Reactivity of immunodominant PTRP peptides with serum specimens from other classes of patients with TB:</strong> The reactivity of 4 immunodominant peptides was checked with serum specimens from different groups of patients and controls. 25-45% of smear negative, HIV negative, TB positive patients' serum specimens recognized these 4 immunodominant peptides. These peptides were also recognized by serum specimens from 60-76% of the HIV positive TB positive patients. <br /></li></ol><p><strong>Concluding remarks:<br /></strong></p><p style='margin-left: 18pt'>In authors words: "These results demonstrate that immunodominant epitopes of carefully selected M. tuberculosis specific proteins can be used to devise a simple peptide based serodiagnostic test for TB."</p></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0tag:blogger.com,1999:blog-1418032058537849255.post-38431958821600869122010-10-09T12:38:00.001-07:002010-10-09T12:41:00.945-07:00Type IV secretion system in Helicobacter pylori: Cag3 function<span xmlns=''><p>Source: Pinto-Santini DM, Salama NR. Cag3 is a novel essential component of the Helicobacter pylori Cag type IV secretion system outer membrane subcomplex. J Bacteriol. 2009 Dec;191(23):7343-52. Epub 2009 Oct 2. PubMed PMID: 19801411; PubMed Central PMCID: PMC2786551.<br /></p><p><br /> </p><p>Bacteria translocate or transfer effector molecules, for examples proteins, toxins, DNA and enzymes, from the interior to the exterior through secretion. The cell wall of bacteria plays an important role in the secretion. The structure of cell wall of Gram negative bacteria (GNB) is more complex than Gram positive bacteria. Thus, secretion is also more complex in GNBs. According to the literature there are at least six specialized secretion systems in GNBs. These are type I secretion system (T1SS), type II secretion system (T2SS), type III secretion system (T3SS), type IV secretion system (T4SS), type V secretion system (T5SS) and twin arginine translocation.<br /></p><p>T4SSs are known to be involved in horizontal DNA transfer to other bacteria and eukaryotic cells, in uptake or release of DNA from/into the extracellular environment, in the secretion of toxins and in the secretion of virulence factors into host cells. It is similar to conjugation system of bacteria and can transfer both proteins and DNA. A lot of research has been going on to define the structure of these T4SS, to identify the molecules which are translocated and effect and mechanism of action of these effector molecules on the host cells. This information is essential to understand the pathogenecity of these bacteria and to design strategies to combat bacterial infections. <br /></p><p>Helicobacter pylori is a GNB and it infects 50% of the world population. The infection can lead to chronic gastric and peptic ulcer disease, gastric carcinoma and mucosa associated lymphoid tissue lymphoma. However, only a small percentage of infected people suffer from H. pylori associated illnesses. Earlier studies have established that infection with strains harboring the cag pathogenecity island (PAI) leads to a much higher risk for development of severe illnesses. Cag PAI is a 40kb stretch of DNA that encodes 27 putative proteins. The T4SS VirB/D4 of plant pathogen Agrobacterium tumefaciens has been studied in great detail. Several of the proteins encoded by cag PAI share sequence similarity with components of A. tumefaciens VirB/D4 T4SS. The activity of cag PAI encoded T4SS is responsible for translocation of effector molecule CagA into the host cells and subsequent induction of proinflammatory cytokines. <br /></p><p>In this paper, the authors have characterized the biochemical role of a H. pylori specific gene, HP0522/cag3, in Cag T4SS. A previous study has shown that Cag3 could interact with HpVirB8, HpVirB7, CagM and CagG. To understand the molecular basis of Cag3 function in T4SS, the authors investigated the subcellular localization of Cag3 protein as well as the interaction that this protein established with other proteins in bacterial cells. <br /></p><p>A brief summary of major results obtained is as follows:<br /></p><p>Results:<br /></p><ul style='margin-left: 38pt'><li><strong>cag3 is essential for Cag T4SS function: </strong>The CagT4SS is responsible for phosphorylation of CagA and induction of IL-8 secretion. Thus, to evaluate whether cag3 is essential for Cag T4SS function, the authors used a null cag3 mutant, a null cag3 mutant complemented by expression of gene at an unrelated locus rdxA and incubated the mutants as well as the wild strains with AGS cells and determined CagA phosphorylation and secretion of IL-8. The mutant strain was unable to translocate CagA as there was lack of phosphorylation of CagA and was unable to induce IL-8 secretion. However, in case of strains complemented with expression of cag3 at rdxA locus, both the CagA phosphorylation and induction of Il-8 secretion were observed.<br /></li><li><strong>Cag3 is a membrane associated protein: </strong>To determine the location of Cag3, the investigators fractionated H. pylori cells and performed immunoblotting of each fraction with antibodies to Cag3. Cag3 was found enriched in the membrane associated fractions.<br /></li><li><strong>Cag3 co-purifies with predicted T4S compartments:</strong> To identify the proteins that interact with Cag3, the authors used affinity purification followed by mass spectrometry. Total extracts from wild type and mutant strains were loaded onto anti-Cag3 affinity columns. The eluates were evaluated for their protein profiles. A number of proteins co-purified specifically with Cag3, i.e. they were absent in eluates of mutant cag3 extracts. Mass spectrometry analysis identified HpVirB7, HpVirD4, CagD and Cag1 as the most specific interactors. Other proteins identified were HpVirB4, HpVirB11, hpVirB10, HpVirB9, HpVirB2 and CagM. <br /></li><li><strong>Cag3 interacts with predicted lipoprotein HpVirB7 independent of CagM:</strong> Previous studies have shown that HpVirB7 is a part of outer membrane subcomplex and previous studies have also suggested that Cag3 and HpVirB7 can interact. Thus, the authors further looked at the interaction of Cag3 and HpVirB7. For this, whole cell lysates from cag3 mutant strains and wild type strains (expressing HpVirB7-3XFLAG) were immuno-precipitated with anti-FLAG and anti-Cag3 antibodies. The authors observed that anti-FLAG antibodies were able to co-immuno-precipitate Cag3 in a wild type strain but not in the mutant strain. Similarly, anti-Cag3 antibodies were able to co-immuno-precipitate HpVirB7-3XFLAG from the wild type strain and not from the cag3 mutant strain. These observations confirm that Cag3 interacts with HpVirB7. The authors next sought to determine whether the Cag3 and HpVirB7 interaction was CagM dependent. The authors observed that anti-Cag3 antibodies were able to co-immuno-precipitate HpVirB7-3XFLAG in a cagM mutant. These observations indicate that Cag3 can interact with HpVirB7 independently of CagM.<br /></li><li><strong>Cag3 and HpVirB7 fractionate in a high molecular weight complex:</strong> To further determine the size of Cag3 complexes in the cell, the authors fractionated whole cell wild type extracts and determined the presence of Cag3 and HpVirB7-3XFLAG in each fraction by immunoblotting with anti-Cag3 or anti-FLAG antibodies. Cag3 was precipitated in two peaks; one peak overlapped with the void volume while other peak corresponded to a 150KDa peak. The size predicted for Cag3 monomer is 55KDa. Thus, these results indicate that Cag3 exists in cell as part of two pools. The lower molecular mass form may represent the soluble form, while the higher molecular mass form may represent the Cag3 membrane associated complex. <br /></li><li><strong>Protein cross linking reveals HpVirB7-CagM and Cag3-CagM interactions:</strong> H. pylori cells (wild type expressing HpVirB7-3XFLAG, mutant HpVirB7, mutant cag3, mutant cag3 complemented with expression of gene at rdxA, and mutant cagM) were cross-lined in vivo with formaldehyde. These cross linked whole cell extracts were fractionated and by SDS-PAGE and immunoblotted with ant-Cag3 or anti-FLAG antibodies. On immunoblotting with anti-Cag3 antibody, monomer sized band as well as several high molecular mass Cag3 containing complexes were observed. These complexes were present even in the HpVirB7 mutants, indicating that HpVirB7 was not present in these complexes. Surprisingly, one complexe was absent in cagM mutant indicating that this complex which was composed of Cag3 and CagM. In contrast, on immunoblotting with anti-FLAG antibody, only two bands were observed. One band corresponded to HpVirB7-3XFLAG while other band was absent in cagM mutant strains, indicating that a dimer containing HpVirB7 and CagM.<br /></li><li><strong>Cag3 and HpVirB7 promote each other's stability:</strong> The mutant and wild type strains were metabolically labeled with Trans35S-label cys-Met during liquid culture growth for a 30 minutes pulse. After the pulse, the two aliquots from each culture were immuno-precipitated with anti-FLAG or anti-CagA antibody. HpVirB7-3XFLAG was less stable in the cag3 mutant strain background compared to the wild type. Cag3 appeared less stable in the absence of HpVirB7, HpVirB9 or HpVirB10.<br /></li></ul><p><br /> </p><p> </p></span>rashmihttp://www.blogger.com/profile/18244204311504656557noreply@blogger.com0